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INTRODUCTION 
Pancytopenia is a triad – anaemia, leukopenia and thrombocytopenia. Incidence 
worldwide is 2 to 5 cases/million population per year and 5 to 12 cases/million 
population per year in the United States (and in other industrialized countries). Incidence 
is approximately twice as high in Asian countries. Peak incidence between ages 15 to 25 
and 65 to 69 [1]. Different studies shows variation inaetiology of pancytopenia. This 
variation not only appreciated in different countries but also in different regions of a 
single country. Many studies from north and south India have implicated megaloblastic 
anaemia as the most common cause of pancytopenia. Aplastic anaemia were found to be 
the most common cause of pancytopenia in a study which was undertaken in Nepal [2]. 
Aplastic anaemia followed by infections such as malaria and lesishmaniasis were the 
major causes of pancytopenia reported from Bangladesh [3]. In contrast, neoplastic 
diseases and radiation have been reported as the most common cause of pancytopenia, in 
Europe and Israel [4]. Pancytopenia with markedly hypocellular marrow and normal cell 
cytogenetics. Pancytopenia is an important clinic - haematological entity encountered in 
our day-to-day clinical practice. It is not a disease entity but a triad of findings that may 
result from a number of disease processes – primarily or secondarily involving the bone 
marrow. Treatment and prognosis of patients with pancytopenia are governed by the 
cause and severity of the underlying disease [1]. 
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AIM AND OBJECTIVES 
To diagnose different conditions producing Pancytopenia on the Basis clinical, 
hematological and/or Bone Marrow Studies.  
To estimate the frequency of different diseases producing Pancytopenia. 
 
The justification for this study: 
 Pancytopenia is only a presentation of a wide variety of diseases and aetiology can be 
varied, depends on the geographical distribution, genetic variations, nutritional status, age 
and many other factors. Yet there have been not much data available on the clinic 
haematological study in pancytopenia in south India. 
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MATERIALS AND METHODS 
Hospital-based prospective study 
Sample size: 1-year duration [july 2016- july 2017] 
Inclusion criteria:  
  Both sexes, age of 18yrs and above. Haemoglobin <10g/dl. Leucocyte count 
<4000/cu.mm. Platelet count <100000/cu.mm [5] 
 The study will be carried out on patients admitted in PSGIMSR (medical ward, 
IMCU, MICU) in pancytopenia patients. 
Exclusion criteria: 
 All patients below the age of 18yrs 
The study is based on prospective collection of data in pancytopenia patient who fulfilled 
the inclusion criteria stated above and admitted in the medical ward in a tertiary care 
centre (PSGIMSR) where systematic computer coding for the registry is used. 
A written informed consent was obtained from all the patients after having fully 
explained the purpose, protocols, and risk involved in the study. All the patients 
underwent a detailed medical history and full physical examination followed by blood 
sampling for investigations i.e complete blood count with peripheral picture, absolute 
reticulocyte count, erythrocyte sedimentation rate, fasting serum vitamin B12 and folic 
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acid level, anaemia profile, TSH, T3, T4, smear for malarial parasite, liver and renal 
function test, and viral markers (HBsAg, HCV, HIV), chest x-ray and ultrasonography of 
abdomen and/or diagnostic Bone marrow aspiration and trephine biopsy subsequently 
carried out under aseptic precaution after obtaining written consent from the patient or 
guardian. If needed Coombs test, EBV, CMV, ANA IF, ANA profile, serum lactate 
dehydrogenase, uric acid Rheumatoid factor, tuberculin test, serum coagulation profile, 
fibrinogen and D-Dimer and special investigation – like Immunophenotyping, 
cytogenetic, lymph node biopsy, immune electrophoresis etc. Data was entered and 
analyzed in statistical software. Frequency and percentage would be computed for 
categorical variables like age and sex distribution, physical findings, peripheral blood 
picture, haematological parameters and common causes leading to pancytopenia. 
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REVIEW OF LITERATURE 
Physiology – haematopoiesis [6] 
In various sites of human body, red blood cells are produce right from intra uterine period 
to adulthood. In the initial stage [fetus] blood cells are formed in the yolk sac followed by 
production of red cells in the liver. There is also some amount of production in the 
spleen. But after about 7 months of gestation bone marrow becomes the major site of 
production and is the only site of production after delivery of the fetus. Except for 
lymphocyte which can be produced in other organs, all other cells are produced in the 
bone marrow. In adult life, major areas of production in the bone marrow are those in 
humerus shaft, spine, femur, skull, pelvis, and thoracic cage.  
The haematopoietic stems cells developed into various lineages depending upon the stem 
cell type. Myeloid cells gives rise to neutrophils, monocytes etc while reticulocyte give 
rise to RBC and megakaryocytes giving rise to platelets.  
The connective tissue cells are within the trabeculae of bone along with fat cells, blood 
vessels, etc. these all are held together by the network of reticulin fibrils. These structures 
are rich in vascular sinusoids and these are the sites were newly produced cells enter. 
Since there are abundant fat cells in the marrow the adequate bone marrow sample is 
absolutely necessary for various laboratory analysis for accurate determination of details 
about haematopoietic stem cells [6, 7] 
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Obtaining bone marrow biopsy plays a pivotal role in making the diagnosis of various 
disorders related to the stem cells of the haematopoietic system. The sample obtained by 
aspiration provide finer details [morphology] compare to the histological examination of 
the core biopsy. The most common method used for obtaining bone marrow biopsy is the 
trephine method. The core biopsy provides more accurate details regarding the cellularity 
of the stem cells when compared to the aspirated specimen. Therefore both the specimen 
[aspiration and core biopsy] are needed to make a more accurate diagnosis.  
 
Figure 1: Primitive and definitive haematopoiesis[AGM - aorta-gonads-
mesonephros, HSC - hematopoietic stem cells] 
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 Primitive hematopoiesis - blood stem cells differentiate into only a few specialized 
blood lineages (typically isolated to early fetal development) 
 Definitive hematopoiesis - multipotent HSCs appear (occurs through the majority 
of  the human lifetime) [8]. 
 
 
Table 1:Bone marrow examination indications [9] 
 
1. Unexplained anaemia, abnormal red cell indices, cytopenias or cytoses 
2. Abnormal peripheral blood smear morphology suggestive of bone marrow 
pathology 
3. Diagnosis, staging and follow up of malignant haematological disorder 
4. Suspected bone marrow metastases 
5. Unexplained focal bony lesion on radiological imaging 
6. Unexplained organomegaly or presence of mass lesion inaccessible for 
biopsy 
7. Microbiological culture for investigations of pyrexia of unknown origin or 
specific infection, e.g – miliary tuberculosis, leishmaniasis, malaria 
8. Evaluation of iron stores 
9. Investigation of lipid/glycogen storage disorders 
10.  Exclusion of haematological disease in potential allogeneic stem cell 
transplant donors 
 
8 
Preliminary procedures [10]: 
 The procedure should be explained in detail to the patient. The past clinical history 
of the patient should be obtained 
 Informed consent should be obtained from the patient 
 A blood count and smear should be obtained if these have not been collected in the 
previous 2 days 
Anatomical sites – preferred site is posterior iliac crest in adults and medial surface of 
the tibia in infants. Another site also useful in special circumstances – anterior iliac crest 
in immobile patients, sternal aspiration when patient receive radiotherapy to the pelvis 
and other site have a dry tap or core biopsy is not required. In obese patient computed 
tomography-guided marrow sampling is useful when difficult to localize iliac crest [11]. 
Bone marrow aspirate: 
Review the patient identification before starting procedure. If posterior iliac crest is 
chosen a site, patient placed in left or right lateral position or prone position. Sterilize the 
site with the sterile solution, place a sterile drape over the site, and administer local 
anaesthesia, infiltrate the skin, soft tissues and periosteum. After giving anaesthesia, 
make an incision through which you can introduce the bone marrow aspiration needle. 
The needle should be advance at an angle completely perpendicular to the bony 
prominence of the iliac crest. Once needle passes through the cortex end enters the 
marrow cavity, it should stay in place without being held. Remove the stylet and aspirate 
approximately 1 ml of bone marrow aspiration into a syringe. If specimen shows 
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spicules; the assistant should use it to make smear slides immediately. If spicules are 
sparse or not present, a new sample should be obtained from a slightly different site [10] 
Bone marrow biopsy: 
The same skin incision to use to perform core biopsy, and adjust the needle for inserting 
at a different angle into bone. Needle introduce in a clockwise rotation with a stylet, after 
entering into periosteum remove the stylet and advance the needle with a clockwise 
motion to a depth of 2 cm. Then twist the needle clockwise and counter-clock wise 
several times and rock it gently back and froth in multiple directions, then slowly remove 
from bone. Then use a probe to remove the marrow from the needle. In adult adequate 
specimen is approximately 2 cm long. Apply pressure to obtain adequate haemostasis, 
then clean the area with alcohol. Place clean or antibiotics – soaked gauze at the incision 
site and using a compression bandage. The bandage may be removed after 24hrs; once 
the bandage is removed, the area should be monitor for infection or delayed bleeding [10] 
Marrow cellularity: 
Cellularity may be altered as increased, normal or reduced at the time of inspecting 
stained film containing marrow particles 
 
 <25% particle – hypocellular 
 75-80% - hypercellular 
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Ratio: 
Myeloid:erythroid ratio based on a count of 200-500 marrow cells. Normal adult 
ratio 3 or 4:1 
Table – 2: Various cell composition of adult bone marrow aspirate 
Cells 95% range Mean [16] Mean [17] 
Myeloblast 0-3 0.4 1.4 
Promyelocytes 3-12 13.7c 7.8 
Myelocyte 2-13 - 7.6 
Metamyelocytes 2-6 - 4.1 
Neutrophils 22-46 35.5 32.1; 37.4 
Myelocyte 0-3 1.6 1.3 
Eosinophils 0.3-4 1.7 2.2 
Basophils 0-0.5 0.2 0.1 
Lymphocyte 5-20 16.1 13.1 
Monocytes 0-3 2.5 1.3 
Plasma cells 0-3.5 1.9 0.6 
Erythroblasts 5-35 23.5 28.1; 22.5 
Megakaryocytes 0-2  0.5 
Macrophages 0-2 2 0.4 
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Table – 3:Various staining patterns of different cellular material 
Cellular component Colour 
Nucleoli  
Chromatin Purple 
Nucleoli Light blue 
Cytoplasm  
Reticulocyte Grey blue 
Erythroblast Dark blue 
Lymphocyte Blue 
Erythrocyte Dark pink 
Metamyelocyte Pink 
Monocyte Grey blue 
Myelocyte Pink 
Neutrophil Orange/pink 
Promyelocyte Blue 
Basophil Blue 
Granules  
Promyelocyte Red or purple 
Eosinophil Red or orange 
Basophil Purple-black 
Neutrophil Purple 
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Toxic granules Dark blue 
Platelet  Purple 
Other inclusion  
Auer body Purple 
Cabot ring Purple 
Howell-jolly body Purple 
Dohle body Light blue 
 
Marrow flim stainings: 
Romanowsky stain is commonly used for staining of blood films, and a good result can 
be obtained. The property of romanowsky dyes unique to it is of making small distinction 
in shaes of staining, and of staining different granules on various shades, depend on 2 
components: azure B [trimethylthionin] and eosin Y [tetrabromo-fluorescein 
[12, 13]
 
Contraindications: 
No absolute contraindications, but relative contraindications are related to the general 
condition of the patient or risk of anaesthesia. An active infection at the proposed site of 
aspiration. 
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Table – 4: Complication of bone marrow aspiration & biopsy [14] 
 Trauma to neighboring structures and soft tissues 
  Infection  
  Retroperitoneal haemorrhage 
  Fractures of underlying bone [patient with osteoporosis] 
 Cardiac tamponade in sternal aspiration [N-1] 
 
Risk factors for haemorrhage   
 Thrombocytopenia, concurrent use of anticoagulants and the presence of 
myeloproliferative disorder. 
 
Diagnostic utility of bone marrow sampling in HIV positive patients[15]: 
Bone marrow sampling used in pyrexia of unknown origin without localizing signs, 
pancytopenia, and staging/investigation of lymphoma. Of 122 bone marrow samples 
taken to investigate pyrexia, 33 [22%] revealed the cause on microscopy: unexpected 
lymphoma in seven [6%], mycobacteriosis in 25 [20%], and toxoplasmosis – 1 [1%]. 
Marrow infiltration was confirmed in 11 of 38 bone marrow samples taken for 
staging/investigation of lymphoma/leukemia. In afebrile patients, of 22 with 
pancytopenia, bone marrow sample showed HIV associated changes in 17 and specific 
diagnoses in 5 [3- mycobacterial infection, 1- haemophagocytic syndrome, and 1- 
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vitamin b12 deficiency]; of 21 with isolated thrombocytopenia, 20 [95%] bone marrow 
sample showed immune thrombocytopenic purpura to be the cause and the remaining 
patient had bone marrow changes of aplasia; of 29 with isolated anaemia, 28 had bone 
marrow changes of HIV associated dysplasia/erythroid dysplasia and 1- had unsuspected 
iron deficiency anaemia; all 10 with isolated leukopenia/neutropenia had bone marrow 
changes ascribed to HIV infection exacerbated by concurrent sepsis or medication; of 4 
bone marrow samples taken for other reasons, 1- showed mycobacterial infection.   
Aetiology of pancytopenia 
Hypocellular marrow: 
 acquired aplastic anaemia 
 inherited aplastic anaemia [fanconi anaemia and others] 
 some myelodysplasia syndrome 
 rare aleukemic leukemia [acute myeloid leukemia] 
 some acute lymphoblastic leukemia 
 rare lymphomas of bone marrow 
Hypercellular marrow: 
 vitamin b12, folate deficiency, alcohol 
 primary bone marrow diseases 
 myelodysplasia syndrome 
 paroxysmal nocturnal hemoglobinuria 
 myelofibrosis 
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 some aleukemic leukemias 
 myelopthisis 
 bone marrow lymphoma 
 hairy cell leukemia 
 secondary to systemic diseases, overwhelming infection 
 systemic lupus erythematosus, sjogren syndrome, hypersplenism 
 brucellosis, sarcoidosis, tuberculosis and atypical mycobacteria 
 
Macrocytic anaemia [16] 
Macrocytosis refers to red blood cells larger than usual. It is strictly a morphologic term 
and does not imply a specific pathophysiology. Macrocytosis can be documented using 
the mean corpuscular volume from an automated hematology instrument, measured in 
femtoliters (fL; 10
-15
 liter) or by observing larger-than-normal RBCs on the peripheral 
blood smear. 
Macrocytosis is defined as an MCV above the upper limit of normal, which varies by 
age: 
 Preterm infants born at ≤25 weeks of gestation – 119 ± 7 fL 
 Term newborns (cord blood) – 106 ± 4 fL 
 Infants and young children – 90 fL 
 Adults – 96 to 100 fL (the higher value may be more appropriate for older adults) 
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RDW 
RBC distribution width is a measure of the variation in RBC sizes. A single uniform 
population of RBCs will have a normal RDW regardless of whether the absolute MCV is 
normal or abnormal. A population of RBCs with varied sizes or two populations of RBCs 
(eg, small RBCs plus reticulocytes) will have a large RDW. 
 
Large RBCs on peripheral blood smear 
RBC size on the peripheral blood smear is estimated by comparing RBCs to the nucleus 
of a small lymphocyte. The normal RBC diameter on the peripheral blood smear is 7 to 8 
microns, approximately the size of the nucleus of a small lymphocyte; RBCs that have a 
greater diameter are considered macrocytic. 
 
Figure – 2: Peripheral blood smear showing a hypersegmented neutrophil (seven 
lobes) and macro-ovalocytes 
17 
 
 
Figure – 3:  High-power view of a normal peripheral blood smear. Several platelets 
(arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of 
relatively uniform size and shape. The diameter of the normal red cell should 
approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) 
should equal one-third of its diameter 
Hypersegmentation of neutrophils signifies megaloblastic “arrest” and thus impaired 
DNA synthesis. The following are the feature of hypersegmentation 
 
- Any neutrophil with 6 or more lobes 
- 5% of neutrophils with 5 lobes 
- Majority have more than 4 lobes 
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A lobe is considered distinct if it is separate from the nucleus or connected by a 
fine chromatin thread. It has been suggested that hypersegmentation can be most reliably 
detected by use of the segmentation index (% of neutrophils with five lobes or more, 
relative to the number of four-lobed neutrophils). 
  
Other diseases associated with Hyper segmented neutrophils are as follows 
1. Iron deficiency anaemia [35, 36] 
2. Uraemia [37] 
3. Hyperthermia [38] 
4. Myelodysplastic syndromes [39] 
5. Langerhans cell histiocytosis [40] 
6. Post irradiation [41] 
7. Drugs such as chemotherapeutic agents, steroids [42], granulocyte colony 
stimulating factor. 
Pathophysiology: 
Red blood cells leave the bone marrow as reticulocytes, which are macrocytic. All 
other macrocytic RBCs are formed as a consequence of inherited or acquired 
abnormalities in RBC maturation, nucleic acid metabolism, membrane composition, cell 
water content, or a combination of these factors [17, 18, 19]. 
1. Increased reticulocytes 
2. Abnormal RBC development 
3. Abnormal RBC membrane 
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Reticulocytosis can occur in any of the following settings: 
 Any hemolytic anemia 
 Repletion of iron, vitamin B12, folic acid, or copper 
 Recovery from bleeding or transient bone marrow aplasia (eg, following 
parvovirus infection) 
 Any other condition associated with increased erythropoietin, such as congenital 
heart disease, erythropoietin-secreting tumors, or "blood doping" 
Table – 5: Differential diagnosis of macrocytosis 
Megaloblastic Nonmegaloblastic False elevation 
 atrophic gastritis 
 enteral 
malabsorption 
 HIV treatments 
 Anticonvulsants 
 Primary bone 
marrow disorder 
 Nitrous oxide abuse 
 Inherited disorder 
 
 Alcohol abuse 
 Drugs abuse 
 Myelodysplasia 
 Hypothyroidism 
 Liver disease 
 Haemolysis 
 Haemorrhage 
 COPD 
 Splenectomy  
 Cold agglutinins 
 Hyperglycemia 
 Marked 
leukocytosis 
 
 
20 
 
 
 
Table – 6: Drug-induced macrocytosis [20-31]: 
Megaloblastic changes: 
 
Allopurinol, Azathioprine, Capecitabine, 
Cladribine ,Cytosine arabinoside (ara-C), 
Fludarabine, Fluorouracil, Gadolinium, 
Gemcitabine, Mercaptopurine, Lamivudine, 
Leflunomide, Zidovudine, Hydroxyurea, 
Mycophenolate mofetil, Methotrexate, 
Nitrous oxide, Stavudine, Pentostatin, 
Teriflunomide, Trimethoprim, Thioguanine 
Reduces folate absorbtion: 
 
Aminosalicylic acid, Ampicillin and 
other penicillins, 
ChloramphenicolErythromycin, 
Estrogens or hormonal 
contraceptives, Metformin, 
Tetracyclines, Nitrofurantoin, 
Phenytoin 
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Reduces B12 absorbtion: 
Proton pump inhibitors (eg, omeprazole, 
lansoprazole), Antacids, Histamine H2 
receptor antagonists (eg, cimetidine, 
ranitidine, famotidine, nizatidine) 
Hemolysis in G6PD deficiency: 
Methylene blue, Pegloticase, 
Primaquine, Dapsone, Rasburicase 
 
Unknown: 
Primidone, Sunitinib, ImatinibTriamterene, 
Valproic acid 
 
 
Of these, most commonly see macrocytosis from hydroxyureafor sickle cell disease, 
chemotherapeutic agents, and antiretroviral therapy (ART) in patients with human 
immunodeficiency virus (HIV) infection. 
Alcohol/liver disease: 
Alcohol-induced macrocytosis occurs even in patients who are folate and cobalamin 
replete and do not have liver disease. Abstinence from alcohol results in resolution of the 
macrocytosis within two to four months. Return of the MCV to normal also confirms the 
diagnosis. 
The mechanism of alcohol-induced macrocytosis is unknown. Acetaldehyde, a metabolic 
breakdown product of alcohol, is capable of inducing membrane changes in red blood 
cell (RBC) precursors and circulating RBCs of individuals with alcohol-associated 
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macrocytosis, through the in vivo production of aldehyde adducts [32]. Acetaldehyde 
also interferes with cell division and may increase cell volume by this mechanism [33]. 
Other forms of liver disease not related to alcohol may cause macrocytosis by effects on 
the lipid composition of the RBC membrane [17]. 
Hypothyroidism: 
Macrocytosis can occur in the setting of hypothyroidism. The mechanism is 
unclear and may be multifactorial in some patients. 
In a series of 202 patients with hypothyroidism from 1976, anaemia was present in 
53 (26 percent) [34]. A subset of 53 individuals who were analyzed in more detail had 
macrocytosis despite normal levels of vitamin B12, folate, and iron. Of these, 13 (25 
percent) had anaemia that resolved upon treatment with thyroxine. All of the remaining 
patients (ie, those with hemoglobin and/or MCV in the normal range) also had a decrease 
in MCV following thyroxine administration. Patients with autoimmune hypothyroidism 
may have concomitant vitamin B12 deficiency caused by autoantibodies to gastric 
parietal cells. In the series of 202 patients, 10 of 118 (8.5 percent) had concomitant 
pernicious anemia. 
The typical MCV in hypothyroidism is mildly increased (in the range of 90 to 100 
fL), which may be due to concomitant defects that cause macrocytosis and microcytosis 
(eg, B12 deficiency plus iron deficiency) [34]. This finding suggests that it may be 
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worthwhile to measure vitamin B12 level in individuals with hypothyroidism who are 
anaemic. 
Diagnosis of megaloblastic anaemia: 
Determining the level of vitamin B12 in the serum is the preliminary step in 
evaluation of megaloblastic anaemia. Quantaphase Radio II assay which is an older and 
non - automated protein binding method was subjected to various studies, has a 
sensitivity of 95-97% [43]. Nowadays it can be done in a fully automated method.This 
method is expected to have sensitivity at least as that of the non-automated method. 
Excluding wholly vitamin B12 deficiency in-spite of normal levels of B12 in the serum is 
not entertained.  
The following are the conditions in which there would be normal or high serum vitamin 
B12 levels even in the face of deficiency  
1. Renal failure  
2. Liver disease 
3. Chronic myeloid leukaemia (CML) and also other myeloproliferative disorders  
4. Chronic exposure to nitrous oxide 
5. Congenital transcobalamin II deficiency 
6. Inborn errors of intracellular B12 metabolism 
7. Parenteral therapy with Vitamin B12 supplements  
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Earlier studies in patients who are elderlyhave shown that increase of serum methyl 
malonic acid (MMA) and plasma total homocysteine (tHCYS) which are the Vitamin 
B12-related metabolites, in a decent fraction of cases with low normal and high normal 
B12 levels. In a study 35% of study population with low-normal B12 levels, i.e. 140–258 
ng/l, and 24% of study population with high normal levels, i.e. >258 ng/l, had increased 
levels of serum methyl malonic acid and plasma total homocysteine; the corresponding 
figures for increased MMA only were 12 and 11% respectively [44]. 
Therefore, some investigators have suggested that vitamin B12 status should be fully 
investigated below a serum B12 level that is quite higher than the lower 95% upper limit 
for this vitamin.  
Some of the conditions are often found to be associated with reduced vitamin B12 assay 
levels in spite store of the vitamin is well with in normal 
1. Pregnancy 
2. HIV infection 
3. Folate deficiency 
4. Patients on anticonvulsant drugs 
5. Myeloma 
6. Transcobalamin I deficiency 
7. Unexplained 
15% of all patients with low serum B12 levels and 15% of patients with low levels in 
patients without B12 malabsorption or metabolite abnormalities likely to occur due to 
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mild and, occasionally, severe TC I deficiency [45]. Diagnosis of the presence of 
Transcobalamin I deficiency is made by Radio immune assay. 
Methylmalonic acid and plasma total homocystreine levels are increased in the face of 
vitamin B12 deficiency. The problem with Methylmalonic acid assay is that it is 
expensive, not widely available and a long turnaround time. Methylmalonic acid assay is 
highly specific for B12 deficiency provided that renal function has been ruled out. 2% of 
cases with folate deficiency and 98% with vitamin B12 deficiency have elevated 
Methylmalonic acid levels [46]. Homocysteine assays are less expensive but the 
availability is wider when compared to serum Methylmalonic acid assays. The sensitivity 
of homocysteine assay is 96% 37 and 91% in cases of B12 and folate deficiency 
respectively. It is useful in patients with in renal failure, alcohol abuse, vitamin B6 
deficiency, hypothyroidism, patients receiving certain drugs (e.g. isoniazid) and inborn 
errors of homocysteine metabolism. The increased methylmalonic acid and homocysteine 
levels in B12 deficiency return to normal after treatment with B12 but not with folate 
[47]. 
 
Holotranscobalamin II (holo-TC II) 
Only 6–20% of the B12 in serum is bound to transcobalamin II (TC II), the transport 
protein involved in delivering B12 to cells; the remainder is bound to transcobalamin I 
(haptocorrin) whose function is uncertain. Measurement of TC II-bound B12 (holo-TC II 
or holo-TC) would be expected to provide a more reliable measure of B12 availability to 
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tissues than total serum B12. With the initial assay methods, holo-TC II appeared to be 
influenced by factors other than B12 status and its specificity for B12 deficiency was 
low.8 Studies with the new radio-immunoassays have shown that holo-TC II is slightly 
more sensitive than serum B12 in detecting individuals with high MMA and tHCYS 
levels [48]. However, they have provided conflicting data on specificity and further 
studies are required before the value of holo-TC II in determining B12 status is 
established [49 – 52] in one study the specificity was found to be 89%.In a recent 
investigation, Chen et al [53] found that deficiency of B12 was much more important 
than impaired B12 absorption in determining holo-TC II levels. There was a considerable 
overlap between serum holo-TC II levels of treated patients with pernicious anaemia and 
control subjects indicating that contrary to previous suggestions holo-TC II levels cannot 
be used as a surrogate for the Schilling test.  
 
Deoxyuridine suppression test [DUST] 
This test gives a measure of the efficiency with which marrow cells methylate de-
oxyuridylate to thymidylate and is abnormal in both B12 and folate deficiency [54-57]. 
Worldwide, it is only performed in a very few laboratories. The DUST is more sensitive 
in detecting B12 deficiency than MMA or tHCYS levels [57] but has the disadvantage 
that it has to be done on bone marrow cells. 
 
Biochemical test for assessing folate status 
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Serum and red cell folate 
Serum or red cell folate assays or both are the initial tests used for the assessment of 
folate status. Most of the folate in serum is in the form of 5-methyltetrahydrofolate 
monoglutamate and that in red cells in the form of various polyglutamates. The red cell 
folate level is a measure of folate status over the preceding three months (i.e. over one red 
cell lifespan). It is generally considered that the serum folate level mainly reflects current 
and recent folate intake and, consequently, is more useful in detecting acute folate 
deficiency than long-term deficiency[58]. On the basis of highly significant statistical 
correlations between serum folate and red cell folate measured by microbiological and 
fully-automated methods [59, 60]. Some have suggested that the serum and red cell folate 
assays give similar information. Though statistically significant, the correlations are weak 
and the regression coefficients of 0.55 found by Jaffe & Schilling [60] and 0.49 found by 
Phekoo et al [59] indicate that only 30% 39 and 24% respectively of the variation of the 
serum folate can be accounted for by variations of red cell folate. 
The accuracy of folate assays and particularly of fully-automated red cell folate assays is 
questionable. The results obtained depend on the assay method - microbiological, 
radioassay, fully-automated or GC-MS [61, 62]. This may arise from differences in the 
method of preparation of the haemolysate and in the completeness of the deconjugation 
of folate polyglutamates to monoglutamates. There are also difficulties in assay design 
resulting from the fact that the red cell-derived monoglutamates do not consist of one 
species of folate molecule but a mixture of folates. 
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The specificity of a low red cell folate in the diagnosis of folate deficiency is poor largely 
because upto 60% of B12-deficient patients have low red cell folate levels. By contrast, 
serum folate levels are increased in 20% and low in only 10% of such patients. In 
practice, folate deficiency is assumed if a low folate level is found together with a normal 
B12 level. If the B12 level is also low, it is important to consider the possibility that the 
primary deficiency is of B12 rather than folate by considering the clinical setting, 
measuring MMA levels (if possible) or by performing a Schilling test. 
Not all patients with a low red cell folate level have metabolic evidence of folate or/and 
B12 deficiency. In one study with a radioassay, low red cell folate levels were found in 8 
of 45 macrocytic patients who gave normal DUST results [63]. 
Plasma total homocysteine (tHCYS) and serum/plasma methylmalonic acid (MMA) as 
mentioned earlier, tHCYS is elevated in both folate and B12 deficiency. The increased 
tHCYS levels in folate deficiency return to normal after treatment with folate but not with 
B12 [64] MMA levels are normal in folate deficiency. 
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One or both levels borderline 
Algorithm for diagnostic testing for suspected vitamin B12 or folate deficiency 
 
 
 
 
 
 
 
 
 
 
 
 
Suspected vitamin B12 or folate deficiency based on one or more of the following: 
 Underlying condition or diet associated with deficiency 
 Macrocytic anaemia with low reticulocyte count 
 Mild pancytopenia 
 hypersegmental neutrophils 
 Unexplained neuropsychiatric abnormalities 
Measure serum vitamin B12 & folate levels 
One or both levels deficient Both levels normal 
Vitamin B12 and/or folate 
deficiency confirmed 
Vitamin B12 and folate deficiencies 
excluded 
Measure MMA and homocysteine 
MMA increased; homocysteine increased – vitamin B12 deficiency  
MMA normal; homocysteine increased – folate deficiency 
MMA normal; homocysteine normal – exclude vitamin B12 & folate deficiency 
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Treatment  
The urgency of correction: 
Most of the people with vitamin B12 or folate deficiency present asymptomatically with 
an incidental laboratory finding or with the slow development of symptoms. Repletion of 
the deficient vitamin can be instituted over a period of weeks in these instances. 
However, in certain cases it may be intervene more urgently: 
 Symptomatic anaemia or neurologic or neuropsychiatric findings, due to the risk 
of adverse events and irreversibility of neurologic deficits 
 Pregnancy, as the developing fetus may be affected 
 Neonates and infants, whose development may be impacted 
However, there is no evidence of benefit from using a higher dose. In extremely rare 
cases of severe deficiency with hemodynamic compromise due to severe anaemia, blood 
transfusion may be given [65, 66]. Vitamin B12 and/orfolic acidshould also be 
administered as appropriate, but these cannot be relied on for emergency therapy because 
improvements in red blood cell production take several days to take effect. 
Available therapeutic preparations: 
 Vitamin B12 (also called cobalamin) is available as cyanocobalamin, which 
contains a cyanide (CN) atom introduced during chemical synthesis and 
hydroxocobalamin. Cyanocobalamin is predominantly used in the United States 
31 
and hydroxocobalamin is predominantly used in Europe; both are effective in 
treating vitamin B12 deficiency [67]. Of note, maintenance doses of 
cyanocobalamin are administered monthly; maintenance hydroxocobalamin is 
administered less frequently (once every two to three months) [65, 66]. 
 Folic acid is also called vitamin B9. Folinic acid (also called leucovorin) is a 
naturally occurring form of reduced folate that is primarily used to prevent 
toxicities of methotrexate; while more expensive, it is effective for treating folate 
deficiency. 
Adverse effects/overdose: 
Vitamin B12 and folate are water-soluble vitamins that are excreted when stores are 
adequate. Rare cases of hypersensitivity or acneiform eruptions with vitamin B12 have 
been reported [65, 66]. Reports of serious adverse effects from administration or intake of 
greater-than-recommended doses have not been observed 
Prevention of vitamin B12 deficiency: 
Specific interventions to prevent vitamin B12 deficiency are unnecessary in the vast 
majority of individuals who consume a normal diet. However, certain settings are 
associated with an increased risk of deficiency 
 Vegan or vegetarian diet 
 Gastric or bariatric surgery 
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 Disorders of the small intestine 
 Neonates born to vitamin B12-deficient mothers 
 Nitrous oxide exposure 
Cobalamine deficiency: 
Apart from specific therapy related to the underlying disorder, the mainstay of treatment 
for cobalamine deficiency is replacement therapy. Parental treatment begins with 1000 
micro g cobalamine daily for 1 week followed by weekly for eight weeks and every 
month later for the rest of patient’s life. 
 
Folate deficiency: 
As for cobalamine deficiency, folate deficiency is treated by replacement therapy. The 
usual dose of folate is 1 mg/d by mouth, but higher doses ( upto 5 mg/d ) may be required 
for folate deficiency due to malabsorption. 
 
Tropical sprue [68] 
Tropical sprue is a clinical syndrome with unknown aetiology typically characterized by 
an acquired chronic diarrheal illness, small bowel mucosal abnormalities & 
malabsorbtion resulting in nutritional deficiency and weight loss. The 1
st
 description of 
tropical sprue termed idiopathic malabsorption of the tropics was attributed to dr.william 
Hillary who studied individuals with chronic diarrhoea in Barbados in 1759. Baker, in 
1974, broadly defined tropical sprue as malabsorption of two or more substances in 
33 
people in the tropics when other causes have been excluded. Klepstein’s definition – 
chronic small bowel diarrhoea with malabsorption of two unrelated substances 
[carbbohydrates & fatty acids], abnormal small intestine histology, exclusion of other 
causes of malabsorption and persistent response to treatment. 
Epidemiology – affects residents, expatriates and tourists of tropical region including 
southeast - Asia, the Indian subcontinent, west Africa, central America, south America, 
the Caribbean, and Puerto rico. India in 2011, dutta et al. estimated the prevalence of 
tropical sprue to be high as 29% in southern Indians diagnosed with malabsorptive 
syndrome. 
Aetiology  
 Exact causative agent still unknown 
 The disease may start acutely or several months after an episode of gastrointestinal 
infection. This initial insult is thought to cause intestinal stasis leading to small 
intestinal bacterial overgrowth and enterocyte injury & dysfunction. 
 Environmental factor, diet, and genetics. 
Pathophysiology: 
 Slowing of small bowel transit time by many mechanism 
 Peptide YY, enteroglucagon, neurotensin, and glucagon like peptide – 1 and stasis 
of fat [ileal brake] are causing enterocyte damage  
 
34 
Clinical manifestation: 
 Chronic profuse diarrhoea, weight loss, statorrhea, bloating, campy abdominal 
pain, anorexia and weakness 
 Nutrient deficiency – folate, vitamin B12, lipid soluble vitamins [A, D, E, K], 
hypoproteinemia, hypomagnesemia and hypophosphatemia 
 Iron deficiency anaemia rare in tropical sprue 
 
Diagnosis: 
Diagnosis of exclusion – exclude other causes of chronic diarrhoea  
 Quantitative stool fat estimation 
 D – xylose testing 
 UGI scopy and deep duodenal biopsy 
Differential diagnosis: 
Celiac disease, lactase deficiency, inflammatory bowel disease, small intestinal bacterial 
over growth, tropical pancreatitis, intestinal scleroderma, amyloidosis, lymphoma, HIV, 
mycobacterim tuberculosis, strongyloides stercoralis, giardia intestinalis, entamoeba 
histolytica, cryptosporidium parvum, cyclospora cayetanesia and isosopora belli. 
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Treatment 
Folic acid supplementation 5-10mg/day for 6 months, though longer duration of therapy 
may be necessary. Folic acid supplementation alone fast recovery and reverse blunting 
villous. 
Those who not responding to folic acid alone, then add tetracycline 250mg four timesa 
day or doxycycline 100mg twice a day for 3-6 months. Response to treatment can take 
weeks to months. 
Figure – 4: possiable mechanism of tropical sprue  
 
 
 
 
 
 
 
Hypersplenism [69] 
Hypersplenism refers to a group of syndromes that involve splenomegaly and peripheral 
cytopenia of various causes. [Enlarged spleen which causes rapid and premature 
destruction of blood cells] 
Acute intestinal infection [small intestine & colon] 
 
Mucosal injury [jejunum & ileum] 
 
Intraluminal bacterial overgrowth                                       high plasma enteroglucagon 
 
Folate deficiency 
 
 
Slowing of small – intestinal transit 
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Classification: 
1. Primary hypersplenism 
2. Secondary hypersplenism 
3. Occult hypersplenism 
Primary hypersplenism -The cause is not clear 
Primary splenic hypersplenism: 
 Non – tropical idiopathic splenomegaly 
 Primary splenic granulocytopenia 
 Primary splenic pancytopenia 
 Splenic anaemia or thrombocytopenia 
Secondary hypersplenism: 
Infections 
Viral hepatitis, brucellosis, subacute or chronic diseases, infectious mononucleosis 
syndrome and malaria 
Alcohol use such as long-term or excessive drinking 
Portal hypertension (PH), such as liver cirrhosis of various causes including post-
hepatitic: cirrhosis, alcoholic cirrhosis, and biliary cirrhosis, fatty liver cirrhosis, 
post-hepatitic autoimmune cirrhosis, schistosomiasis-induced cirrhosis, and drug-induced 
cirrhosis, as well as hemosiderosis and portal vein thrombosis 
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Granulomatous inflammation  
Systemic lupus erythematosus, rheumatoid arthritis, chronic syphilis, chronic 
tuberculosis, felty’s syndrome, and sarcoidosis 
Malignancies  
Splenic lymphosarcoma, leukemia, and cancer metastasis 
Chronic hemolytic diseases 
Hereditary spherocytosis, autoimmune hemolytic anaemia, and thalassemia 
Lipidosis  
Gaucher's disease, and Niemann-Pick disease 
Myeloproliferative disorders  
Polycythemia vera, chronic myeloid leukemia, and myelofibrosis 
Other diseases - hemophagocytic syndrome (HPS), relatively benign hamartoma, splenic 
cyst, splenic artery aneurysm, and cavernous hemangioma.  
The most common hypersplenism is secondary to post-viral hepatitis, cirrhotic PH. 
Occult hypersplenism: 
Both primary & secondary hypersplenism, if the underlying cause is not serious, together 
with benign bone marrow hyperplasia and sufficient bone marrow compensation, 
peripheral cytopenias may not occur. In this case, hypersplenism becomes occult with no 
symptoms.  
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However, once the bone marrow hematopoietic function is suppressed by factors such as 
infection or drugs, monolineage or multilineage peripheral cytopeniaoccurs, accompanied 
by clinical symptoms, which is not classified as occult hypersplenism. 
 
Pathogenesis: 
The exact pathogenesis of hypersplenism induced peripheral cytopenia is still 
inconclusive, several mechanism has been identified. 
Retention in the spleen 
In portal hypertension, the spleen can increase 8 – 10 times its normal size [hyperemic 
splenomegaly], as consequence, there is retension of large number of WBC, RBC, and 
platelets in the spleen. Number of retained blood cells can be 5.5 – 20 times higher than 
the normal level, thus facilitating capture, phagocytosis or destruction of blood cells by 
phagocytes resulting in peripheral cytopenias.  
In 1965, aster found by using 
51
Cr-labeled platelets that under normal circumstances, 
approximately one – third of platelets are stored in the spleen, and the remaining two 
third in the blood circulation. 
In hypersplenism, 50 – 90% of platelets are retained in the enlarged spleen resulting in a 
reduction of platelets in the circulating blood. 
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Diagnostic criteria of hypersplenism 
1. Anaemia, leukopenia or thrombocytopenia, either singly or in combination 
2. Cellular or hyperplastic bone marrow 
3. Splenomegaly 
4. Significant improvement in the peripheral blood picture following splenectomy 
Treatment 
 Non - surgical treatment  
 Treat etiological cause and treat concomitant disease process 
 
Etiological treatment  
Hypersplenism has many causes, and treatment should direct specific causes. 
Kalambokis and tsianos [70] observed an increased incidence of peripheral cytopenia in 
liver cirrhosis patients, this related to hypersplenism, and activation inflammatory 
mediators, by endotoxin produced by intestinal bacteria. In this situation should be 
prescribed for antibiotics to counteract endotoxemia in patients with cirrhosis to increase 
blood cell count. 
Zucchini et al [71] fount that electromagnetic hyperthermia was effectively treating 
thrombocytopenia in a rat model cirrhotic hypersplenism. 
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Chernykh et al [72] report satisfactory outcomes achieved by autologous stem cell 
transplantation in the treatment of peripheral cytopenias due to cirrhotic portal 
hypertension. 
 
Zhang et al [73] proposed that phosphatidylinositol 3-kinase regulatory subunit 1 
[PIK3R1] may play an important role in the pathogenesis of portal hypertension and 
regulating the inhibition of macrophage activity, and that inhibition of PIK3R1 
expression may potentially be useful for the treatment of portal hypertension and 
hypersplenism 
External irradiation & ablation 
Kenawi et al treated eight patient with liver cirrhosis, splenomegaly and hypersplenism 
by externally irradiating the spleens using radioactive co – 60. Laboratory data showed 
that the hemogram returned to completely normal in two patients and partially normal in 
three patients. Moreover, remission of chronic splenic pain was obtained in all patient 
and no significant complications were reported [40]. Ismail et al [69] also observed 
increased platelet counts & improved splenic pain in patients treated with splenic 
irradiation. Feng et al [69] treated patient with hypersplenism using radiofrequency 
ablation which give effective symptoms relief while maintaining normal blood Tuftsin 
levels essential for the anti – infective and antitumor functions of the body. 
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Partial splenic artery embolization 
In 1979, spigos et al used partial splenic artery embolization for the first time to treat 
hypersplenic patients with success [74]. Thereafter, it has been applied in the treatment of 
portal hypertension, hypersplenism, and bleeding esophagogastric varices [75]. This 
procedure not only increases platelet & leukocyte count [38], but also reduces splenic 
size, improves pancytopenia [72], and stimulates the immune system [76]. Despite some 
clinical success in treating splenomegaly and hypersplenism, the indications for partial 
splenic artery embolization are limited due to serious complications, such as splenic 
infarction and abscess, which could result in a high risk of death (77). 
 
Total splenectomy 
Liver transplantation 
While liver transplantation for the treatment of hypersplenism has not been reported, 
hypersplenism is often developed from liver cirrhosis. Severe cirrhosis is often associated 
with serious hypersplenism.Liver transplantation may reduce the splenic size and the 
portal pressure, decrease the risk factors of bleeding, and eventually eliminate hyper-
splenism (78).  
 
Absolute indications for splenectomy [79] 
 
Splenic trauma, splenic rupture, splenic abscess (e.g. tuberculous infection), splenic cysts, 
neoplasm, aneurysm of splenic artery. 
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Table – 7: Relative indication of splenectomy 
1. Blood and reticuloendothelial disease 
a) Haemolytic 
i. Congenital haemolytic anaemia  
ii. Acquired haemolytic anaemia  
iii. Thalassaemia 
b) Haematological malignancy 
i. Acute leukemia  
ii. Chronic myeloid leukemia  
iii. Chronic lymphatic leukemia  
iv. Lymphoma (Hodgkin’s)  
c) Myeloproliferative disorders 
i. Polycythaemia vera 
ii. Myeloid metaplasia (myelofibrosis) 
d) Thrombocytopaenic disorders 
i. Acute ITP  
ii. Chronic ITP 
2. Infective and inflammatory 
a) Parasites (hydatid)  
b) Protozoal (malaria)  
c) Inflammatory (Felty’s syndrome) 
 
3. Neoplastic 
a) Angioma  
b) Cysts 
c) Metastases  
4. Cryptogenic 
a) Tropical splenomegaly  
b) Non-tropical splenomegaly  
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5. Congestive 
a) Portal hypertension 
i. Intrahepatic  
ii. Extrahepatic  
 
6. Metabolic storage disorders 
a) Amyloidosis 
b) Gaucher’s disease 
 
 
Complication of splenectomy   
 Haemorrhage 
 Pulmonary atelectasis and pneumonia 
 Sympathetic pleural effusion 
 Subphrenic abscess/cellulitis 
 Gastric ileus 
 Acute pancreatitis 
 Severe thrombosis after splenectomy for myeloproliferative disorders 
 
Aplastic anaemia 
Aplastic anaemia is defined as pancytopenia with hypocellular bone marrow in the 
absence of an abnormal infiltrate and with no increase in reticulin [80]. Aplastic anaemia 
is a heterogenous group of disorder that result in pancytopenia and hypocellular bone 
marrow. 
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Stem cell failure mechanism 
Aplastic anaemia is a specific disease entity reflecting a deficiency of haematopoietic 
stem cells, resulting in peripheral pancytopenia and bone marrow aplasia. In contrast, 
bone marrow failure is a more encompassing term that describes pancytopenia from a 
variety of different mechanisms. Examples include bone marrow replacement by tumor 
or fibrosis, and myelodysplasia, in which the stem cells are malignant, may be present in 
increased numbers, but do not mature normally. 
 
Stem cell failure can be congenital or much more often, acquired. The major causes of 
acquired aplastic anaemia are exposure to wide variety of chemicals and drugs, ionizing 
radiation, and some viruses. It may rarely complicate orthotopic liver transplantation; 
aplastic anaemia in this setting has a very poor outcome except in those patient who 
develop the disorder in the context of fulminant hepatic failure [81] 
 
Aplastic anaemia has also occurred in patient with other immune disorder & occasionally 
in pregnancy [82, 83]. The aplasia associated with pregnancy is frequently self-limited, 
ending with delivery.  
Idiopathic aplastic anaemia 
The causes remains obscure in most patients with acquired aplastic anaemia. Several 
observations are consistent with destruction or suppression of the stem cell by 
autoimmune mechanism [84, 85] 
 
 Many of these patients respond to immunosuppressive therapy 
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 There is an association of aplastic anaemia with the rare immunologic disease 
eosinophilic fasciitis  
 
 Aplasia can occur in the context of graft-versus-host disease following allogenic 
hematopoietic cell transplantation 
 
 Bone marrow lymphocytes of patients with aplastic anaemia can inhibit 
hematopoiesis when cultured with patient or normal marrow 
 
 Oligoclonal or monoclonal expansions of CD8+ T cells have been found in 
patients with idiopathic aplasia anaemia, as well as in the closely releated disorder 
paroxysmal nocturnal hemoglobinuria 
 
 In a small study, T-cell receptor zeta chain expression was decrease in the majority 
of patients with aplastic anaemia, comparable to that seen in other autoimmune 
diseases; expression was decreased regardless of disease activity or treatment 
status  
Most cases are idiopathic, presumably an autoimmune disorder. Some acquired 
aplastic anaemia cases are associated with bone marrow toxicity from chemical & 
physical agents, viral infections, mycobacterial infections, & other causes. Rarely, several 
inherited bone marrow failure syndromes have aplastic anaemia as a key pathological 
component. Family member of these patients should be screened. Screening of family 
member should also be offered to 10% of aplastic anaemia patient with spontaneous 
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mutation or haploinsufficiency of telomerase. The condition present with skin pallor, 
ecchymosis, petechiae, and possible fever.  
Aplastic anaemia various causes 
o Idiopathic; presumed autoimmune [70-80%] 
o Ionizing radiation 
o Viral infections 
Epstein – barr virus 
HIV 
Dengue 
Hepatitis virus 
Parvovirus 
o Chemical exposure, including cytotoxic agents 
Benzene 
Sulphur or nitrogen mustard and congeners 
Anti metabolites 
Anti mitotic agents 
Inorganic arsenic 
Dichlorovinylcysteine 
Insecticides 
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o Medications 
Anti microbial agents – chloramphenicol, organic aresenicals, qquinacrine, 
penicillamine 
Anti convulsant – acetazolamide, carbamazepine, hydantoins, trimetadione 
Anti thyroid drugs 
Anti diabetic drugs 
Estrogens 
Anti histamines 
Analgesics 
Sedatives & tranquilizers 
Gold compounds 
o Associated 
Inherited bone marrow failure syndrome [eg – fanconi anaemia, dyskeratosis 
congenital, shwachman-diamond syndrome, congenital amegakaryocytic 
thrombocytopenia] 
Paroxysmal nocturnal hemoglobinuria 
Myelodysplastic syndrome 
Acute myelogenous leukemia 
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Investigations: 
 Complete blood count and reticulocyte count, blood film examination, HbF% in 
children, bone marrow aspirate and trephine biopsy, including cytogenetics, 
peripheral blood chromosomal breakage analysis to excludeFanconi anaemia if 
<50 years, flow cytometry for GPI-anchored proteins (see note belowconcerning 
Ham test)*, urine haemosiderin if ham test positive or GPI-anchored 
proteindeficiency, vitamin B12 and folate, anti-nuclear antibody and anti-dsDNA, 
peripheral blood gene mutation analysis for dyskeratosis congenital DKC1, TERC, 
?TERT) if clinical features or lack of response toimmunosuppressive therapy. 
 
Severity of aplastic anaemia [86]: 
1. Severe aplastic anaemia [camitta et al, 1975] – bone marrow cellularity <25%, or 
25 -50% with residual haemopoietic cells* 
 
           2/3
rd
 of the following: 
 Neutrophil count 0.5 x 109 /l 
 Platelet count <20 x 109 /l 
 Reticulocyte count <20 x 109 /l 
 
2. Very severe aplastic anaemia [bacigalupo et al 1988] – as for severe aplastic 
anaemia but neutrophil count <0.2 x 10
9 
/l 
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3. Non – severe aplastic anaemia – patient not fulfilling criteria for very severe and 
severe aplastic anaemia 
 
*Cellularity should be determined by comparison with normal controls 
(Tuzuner & Bennett, 1994) 
 
Table – 8: Differential diagnosis of pancytopenia and a hypocellular bone marrow 
 Hypocellular MDS/acute myeloid leukemia  
 Hypocellular acute lymphoblastic leukemia  
 Hairy cell leukemia  
 Lymphoma 
 Mycobacterial infection – commonly in atypical organisms 
 Anorexia nervosa or prolonged starvation  
 
Treatment 
Supportive care, including antimicrobials, erythrocyte & platelet transfusion, bone 
marrow transplantation, and immunosuppressive therapy. Use of offending drugs or 
agents that appear to be causing the marrow failure must be discontinued. In the past, the 
diagnosis of aplastic anaemia was associated with a 67% mortality, most commonly a 
consequence of infection resulting from neutropenia or bleeding resulting from 
thrombocytopenia. 
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Aplastic anaemia should be considered in all patients with pancytopenia. Common causes 
of anaemia [eg – iron deficiency, folate/B12 deficiency, alcoholism, acute sepsis, or 
marked inflammatory condition flares] should be ruled out before proceeding to a bone 
marrow biopsy. Definitive diagnosis is based on a bone marrow biopsy showing 
hypocellularity without another diagnosis to account for the hypocellular condition. 
Normal cytogenetics or no chromosomal abnormalities are the most common findings. 
Finding unbalanced lesions common to myelodysplastic syndrome suggest either a 
possible disease transformation from aplastic anaemia to myelodysplastic syndrome, or a 
primary diagnosis of hypocellular myelodysplastic syndrome. From a practical 
perspective, the critical issue is to distinguish severe and very severe aplastic anaemia, 
which usually require treatment, from moderate aplastic anaemia, which usually requires 
only monitoring & supportive care. 
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Bone marrow transplantation vs immunosuppressive therapy in aplastic anaemia 
 
 
Figure – 4: The above graph shows the data obtained from the study conducted by 
Doney.k et al it shows the survival was better in the group of 168 aplastic anaemia 
patients who underwent bone marrow transplant therapy when compared to the group of 
227 aplastic anaemia patients who underwent immunosuppersive therapy [87]. 
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Figure – 5: The above graph from the data obtained in the study conducted by Storb.r et 
al shows that the incidence of graft versus host disease was less in group of patients who 
were conditioned with antithymocyte globulin prior to bone marrow transplantation, 
similarly the survival was better in the above mentioned group compare to bone marrow 
transplantation patients who were conditioned with cyclophosphamide alone [88]. 
  
53 
RESULTS 
 
The total population was 50[n]. The various aetiologies of pancytopenia identified 
by this study population. Most common aetiology is megaloblastic anaemia accounting 
for 50%. Second most common causes was haematological malignancies accounted for 
16%. Followed by decreasing trend – hypersplenism 10%, aplastic anaemia 8%, dengue 
fever with pre-existing iron deficiency anaemia 8%, systemic lupus erythematosus 4%, 
hemophagocytic lymphohistocytosis 4%. 
 
 
 
megaloblastic 
anaemia
50%
haematological 
maligncies
16%
hypersplenism
10%
aplastic anaemia
8%
autoimmune
4%
others
12%
figure - 6: distribution of various causes in pancytopenia
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Table – 9: Showing causes, no of patients and percentage in pancytopenia patients 
Causes No of patients Percent 
Megaloblastic anaemia 25 50.0 
Hypersplenism 5 10.0 
aplastic anaemia 4 8.0 
Dengue fever with pre-existing iron 
deficiency anaemia 
4 8.0 
systemic lupus erythematosus 2 4.0 
plasma cell dyscrasia 2 4.0 
myelodysplastic syndrome 2 4.0 
Hemophagocytic lymphohistiocytosis 2 4.0 
acute myeloid leukemia 1 2.0 
Non - hodgkins lymphoma 3 6.0 
Total 50 100.0 
 
The incidence of malignancies in study population is 16%. The malignancies that 
were present in the study population were as follows. 
 
3
2
2
1
Figure - 7: Malignanices noted in pancytopenia patients in 
study population
non hodgkins lymphoma plasma cell dyscrasia
myelodysplastic syndrome acute myeloid leukemia
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The mean age of the study population is represented in the following figure. Mean age of 
patients with SLE was noted to be lower when compared to others as expected. 
Malignancies [red bar] were noted to have a higher mean when compared to all cause 
mean age. 
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Figure 8: Mean age for various causes
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Gender distribution of various causes – megaloblastic anaemia & malignancies were 
more common in males than females.  
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Figure 9: Gender distribution 
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Age wise distribution in pancytopenia patients, more common age group fall under 41-
50yrs & 61-70yrs. 
The mean of various laboratory parameters are considered below in following table. 
Table – 10: Represents the mean, standard deviation, range of various parameters, 
haemoglobin, WBC, platelets, MCV, RDW, MPV [minimum to maximum]. 
Mean total WBC – 2.54±0.99 
Mean haemoglobin – 5.8±2.1 
Mean platelet – 49.12±31.75 
 Minimum Maximum Mean Std. Deviation 
HB 2.00 10.00 5.8140 2.10994 
WBC .40 3.90 2.5420 .99757 
Platelet 3.00 99.00 49.1200 31.75650 
MCV 54.00 133.00 93.6980 20.22669 
RDW 17.10 42.00 28.4083 8.09788 
MPV 8.00 11.60 9.3417 .99909 
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Clinical features: 
The most common presenting complaints of patients presenting with pancytopenia 
was easy fatigability 58%, fever – 40%, breathing difficulty & loss of appetite – 30%. 
Bleeding manifestation was the presenting complaint in only 14%. 
 
 
  
58%
40%
30%
30%
14%
Figure 10: clinical presentation
easy fatigueability fever breathing difficulty loss of appetite bleeding manifestation
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Physical examination – most common physical finding in our study group; pallor 88%, 
splenomegaly 28%, pedal oedema 24%. 
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Figure 11: Physical Finding
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The MCV of megaloblastic anaemia when compare with patient with non megaloblastic 
causes of pancytopenia and all cause MCV is shown in figure.  
The mean MCV of patients with megaloblastic anaemia is 107.5 which is much higher 
than the non megaloblastic anaemia which is 79.9.  
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Figure 12: MCV in patient with pancytopenia
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This figure represent RDW in various causes of pancytopenia. The RDW in patient with 
megaloblastic cause for pancytopenia was much higher than that of non megaloblastic 
cause for pancytopenia. 
 
 
  
0
5
10
15
20
25
30
Non Megaloblastic 
anaemia
Megaloblastic anaemia Total
22.2
28.6783 28.4083
Figure 13: RDW in patients with pancytopenia
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This figure represent MPV in megaloblastic & non megaloblastic grouph. Mean platelet 
volume was used as a criteria to distinguish different cause for pancytopenia in other 
studies. In our study MPV was almost same between in megaloblastic [9.37±100] and 
non megaloblastic causes [9.34±0.99] 
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Table–11: Shows peripheral blood picture in pancytopenia patients. Anisopokilocytosis 
& hypersemental neutrophils was the predominant finding in megaloblastic anaemia. 
Immature WBC noted in acute myeloid leukemia, myelodysplastic syndrome, plasma cell 
dyscrasias.  
Causes 
No. of 
Patients 
A B C D E F G 
Megaloblastic anaemia 25 24 3 15 3 5 0 0 
Hypersplenism 5 5 0 0 0 0 0 0 
aplastic anaemia 4 3 0 1 1 0 0 0 
dengue fever with pre – existing iron 
deficiency anaemia 
4 2 0 0 2 1 0 0 
systemic lupus erythematosus 2 1 0 0 1 1 0 0 
plasma cell dyscrasias 2 2 1 0 0 1 0 0 
myelodysplastic syndrome 2 2 1 1 1 0 0 0 
Hemophagocytic lymphohistiocytosis 1 1 0 0 0 0 0 0 
acute myeloid leukemia 1 0 1 0 0 0 0 0 
non hodgkins lymphoma 3 2 0 0 1 0 0 0 
Total 50 43 6 17 10 8 0 0 
 
 
A – ANISOPOIKILOCYTOSIS               B – IMMATURE WBC       
C- HYPERSEGMENTED NEUTROPHILS  D – ACTIVATED LYMPHOCYTES     
E – LYMPHOCYTOSIS           F – IMMATURE RBC          
G – INCREASED RETICS 
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The various peripheral smear findings in patient with megaloblastic anaemia are as 
follows. The most common finding in our study is tear drop cells followed by 
hypersegmented neutrophil & elliptocytes. 
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Figure 15: Peripheral blood picture in megaloblastic anaemia (n-25)
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This figure represent bone marrow aspiration finding in pancytopenia patients. The most 
common finding in our study is hypercellular marrow [68.08%] followed by 
normocellular marrow [14.89%]. Out of 50 patients, 3 patient bone marrow aspiration 
and biopsy was not done.  
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Figure 16: Bone Marrow aspiration (n-47) 
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The cause for megaloblastic anaemia in our study group were as follows. Combined 
vitamin B12 & folate deficiency [52.0%] was the most common cause. Followed by 
isolated vitamin B12 deficiency [36.0%]. Isolated folate deficiency - 8% 
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Figure 17: nutrient deficiencies in patients with megaloblastic anaemia 
(n-57)
67 
Of the 25 patient with megaloblastic anaemia 40% (n-10) were vegetarian diet, whereas 
60% (n-15) consumed mixed diet. 
 
 
Endoscopic finding in patient in patient with megaloblastic anaemia are represented in 
the figure below. 
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Figure 19: Endoscopic finding in  patients with megaloblastic anaemia
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Out of all the patients with megaloblastic anaemia as a cause for pancytopenia 17 patients 
consented & underwent endoscopy. Of these patients 10 [58.82%] had tropical sprue 
whereas only 41.17% had no evidence of tropical sprue in the biopsy. 
 
 
MCV in megaloblastic & non megalobalastic anaemia. In our study, MCV value high in 
megaloblastic anaemia than non megaloblastic anaemia. 
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Figure 21: MCV in megaloblastic Vs non megaloblastic pancytopenia
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DISCUSSION 
 
Most of the studies that have been done on pancytopenia in adults have included 
paediatric population as well. It is very important to do study specifically in adults 
because the physician treating children and adults are different and more importantly the 
aetiological of pancytopenia in paediatric is very different from the adult population. 
Various studies that have beendone in the paediatric population have shown that most 
common cause of pancytopenia is likely to be malignancy. In a study done by gupta et al 
at Banaras in children the most common cause for pancytopenia in children was aplastic 
anaemia 43% followed by acute leukemia 25%. Megaloblastic anaemia was the only the 
third common cause for pancytopenia in those children accounying only to about 6.7% of 
children. In a study done by zeb jan et al in Peshawar, Pakistan in children the total 
number of children included were 205 [age group 6 month to 14yrs]. In that study the 
most common cause for pancytopenia was aplastic anaemia which constituted 28.3% 
followed by haematological malignancy 23.9% & megaloblastic anaemia 19.5%. in 
another study done by khan et al in Pakistan where about 279 pancytopenic children were 
analysed the most common cause for pancytopenia was acute leukemia 32.2% followed 
by aplastic anaemia 30.8% & megaloblastic anaemia 13.2%. Though there have been few 
studies done in the adult population with regards to pancytopenia the major drawback of 
most of these studies has been that they have been done including quite a large number of 
paediatric patients which actually misguides the treating physician and does not give a 
clear view of the prevalence of the various etiological factors in adult population. 
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Figure 23: Comparison of  age group in others & current study
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The male to female ratio in most patients show a male preponderance in almost all 
studies. In our study showed a male: female ratio 1:1 
TABLE–12: COMPARING MALE: FEMALE RATIO IN OTHER STUDIES 
STUDY AUTHOR MALE : FEMALE RATIO 
Savage DG et al [113] 1.3:1 
Tilak et al [110] 1.14:1 
B N Gayathri et al [111] 1.2:1 
Jha A et al [1122] 1.5:1 
Kumar et al [110] 2.1:1 
Khunger et al [108] 1.2:1 
Kodke et al  1.3:1 
Current study  1:1 
 
Below Table– 13: Showing the author of the study, year of study, no of cases and study 
location. 
Author Location Year of study No of cases 
Elizabeth et al USA 2012 250 
Imbert et al France 1989 213 
Savage et al Zimbabwe 1999 134 
Jha A et al Nepal 2008 148 
Kumar et al Chandigargh, India 2001 166 
Khunger et al New Delhi, India 2002 200 
B N Gayathri et al Davangere, India 2011 104 
Tilak et al Chandigargh, India 1999 77 
Current study Coimbatore, India 2017 50 
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Figure 24: Comparison of haemoglobin values between our study and study done by 
gayathiri et al in megaloblastic group 
 
 
Figure 25: Comparison of total WBC values between our study and study done by 
gayathiri et al in megaloblastic group 
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73 
Figure 26: Comparison of platelet values between our study and study done by 
gayathiri et al in megaloblastic group 
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The most common causes of pancytopenia in various studies outside India are 
represented in the following figure. Imert et al & Elizabeth et al study clearly shows most 
common cause for pancytopenia is malignancies. Savage dg et al study done in 
Zimbabwe which shows most common cause is megaloblastic anaemia. Study done in 
nephal – jha a et al shows most common cause is aplastic anaemia followed by 
megaloblastic anaemia. In our study the most common cause for pancytopenia was 
megaloblastic anaemia followed by malignancies. 
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FIGURE 27: COMPARISON OF MOST COMMON CAUSES FOR 
PANCYTOPENIA WITH STUDIES DONE OUTSIDE INDIA
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The figure shows current study compare with other Indian studies. Khunger et al, 
Gayathiri et al, Tilak et al shows most common cause for pancytopenia was 
hypersplenism, followed by megaloblastic anaemia. Kumar et al study shows common 
cause was megaloblastic anaemia. Current study shows most common cause is 
megaloblastic anaemia followed by hypersplenism.   
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FIGURE 28: COMPARISON OF MOST COMMON CAUSES FOR 
PANCYTOPENIA WITH STUDIES DONE IN india
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Hypersegmented neutrophils are characteristic feature of megaloblastic anaemia and the 
incidence has varied in different studies. In our study the presence of hypersegmental 
neutrophil was 60% when compared to 51.35%; 84.9% and 68% in gayathiri et al; tilak et 
al and chan et al respectively. 
Figure 29: shows hypersegmented neutrophils prevalence in  peripheral smear of 
megaloblastic anaemia patients in various studies. 
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Nucleated RBCs though not presented in classical literature has been present in 24% of 
the megaloblastic population in our study whereas the study by gayathiri et al reported no 
such finding; khunger et al has reported nucleated RBCs in 12.5% of the megaloblastic 
study population [n-144]; tilak et al have reported the presence of nucleated RBCs to be 
24.5% in the megaloblastic subgroup in their study [n-53]. 
Figure 30: percentage of the megaloblastic group presenting with nucleated RBCs 
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RECOMMENDATIONS 
 All patients presenting with pancytopenia should be evaluated for megaloblastic 
anaemia and other correctable factors 
 Vitamin B12 & folate assay are useful tests in the evaluation of megaloblastic 
anaemia 
 Upper GI endoscopy & deep duodenal biopsy should be done in all patients 
diagnosed to have megaloblastic anaemia to evaluate for tropical sprue 
 Bone marrow aspiration & biopsy need not be done in most patients with a clinical 
picture of megaloblastic anaemia 
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CONCLUSION 
 
From our study it can be proposed that inspite of numerous etiology available for 
pancytopenia and its various manifestations the most common etiology is the 
megaloblastic anaemia. 
And the most common reason for megaloblastic anaemia is vitamin b12 deficiency. So it 
can be suggested that screening of  b12 deficiency should be the intial screening test for 
evaluation of megaloblastic anaemia irrespective of the diet of the patient because it is 
not only the most common cause of megaloblastic anemia  but is also present in patients 
who consume mixed diet. Other investigations like UGI scopy can be followed through if 
needed based on clinical scenario. Other conditions like malignancy, hypersplenism and 
aplastic anaemia which are the next most common cause in our study should also be kept 
in mind while ordering further investigations 
The findings of the above study also indicates that prompt identification of patients with 
megaloblastic anemia and treating the underlying cause in intial stage itself can reduce 
the incidence of pancytopenia and its various complication. 
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LIMITATIONS  
1. This study was conducted in particular region & most of the study population were 
natives of  the same location, hence the race and regional variability cannot be 
comment upon 
2. Few of the patients in this study denied bone marrow biopsy and UGI scopy 
hence, those finding not included in this study 
3. Few of these patients were not followed through due poor patient compliance 
hence, response to therapy were not looked into in detailed. 
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NAME IP NO AGE SEX DIAGNOSIS SYMPTOMS EXAMINATION HB WBC PLT PERIPHERAL SMEAR ANAEMIA PROFILE BA BX OTHER TEST FOLLOW UP
rehana begum i17002036 53 f acute myeloid leukemia fever, fatigueability hepatomegaly+ 7.3 2.2 13
ps- pancytopenia & myeloblast. Mild anisocytosis. Blast 15%. One blast demonstrate auer 
rods+.immature wbc +++ 
s.iron-80, tibc-236, ferritim-936 acute myeloid leukemia with dysplasia of myeloid lineage hypocellular marrow with features compatiable with bone 
marrow aspiration diagnosis of acute leukemia
mcv - 99, vit b12 - 394, folate-3.52, tsh-2.970, hiv,hbsag,hcv - negative. Scrub 
typhus-neg, cmv-neg, weilfelix test - neg. ana profile - neg. EBV-neg. usg abd- 
hepatomegaly
mayilsamy i16036799 41 m
megaloblastic anaemia-vit b12 & 
folate deficiency [mixed diet] dyspnea, fatigueability, vomiting
pallor, icterus+, 
spleenomegaly+
4.6 3.2 82
moderate anisopoikilocytosis & microcytic normochromic to macrocytic hypochromic. 
Anisopikilocytosis + & hypersemented neutrophils +,polychromasia+,elliptocytes+,tear drop cells+.
nd
hypercellular & florid erythroid hyperplasiam with 
predominant megaloblastic maturation. Occassional gaint 
metamelocytes are seen hypercellular marrow - erythroid hyperplasia
MCV- 115,rdw- 24.4,mpv -10.1, vit b12 -<50.0, folate-1.32, LDH- 2333, 
hepatoglobin- <10, esr-97, tsh- 2.80, usg abd- spleenomegaly, duodenal biopsy - 
tropical sprue[scalloped duodenal folds]
20 days later - rpt Hb-12, 
tc- 7.8, PLT- 261
Thiyagu i16037240 29 m
megaloblastic anaemia-vit b12 & 
folate deficiency  [veg] fatigue ability, dyspnea pallor+, pedal edema + 4.9 3.9 9
macrocytic normochromic anemia - anisopoikilocytosis +, lymphocytosis +,elliptocytes+,tear drop 
cells+,target cells+,polychromasia+,basophilic stippling+,howell jolly bodies+.
s.iron-121, tibc-133, ferritin- 
>2000
hyercellular & shows marked erythroid hyperplasia 
characterized by normoblastic as well as megaloblastic 
maturation. Myeloid series shows sequential maturation 
with occasional gaint band forms.
hypercellualr marrow - erythroid hyperplasia with megaloblastic changes
MCV-108,rdw-25.7,mpv-10.6, ldh-477 corrected reticulocyte count - 0.4%, 
dengue serology-neg,EBV,CMV -neg, viral serology - neg. ana profile - ss-A +, SCL- 
70 +. Usg abd - minimal ascities, minimal rt pleural effussion, duodenal biopsy- 
tropical spure[lax lower esophageal sphincter & scalloping of duodenal 
folds],vitamin b12-125,folate-4.22
2 months later rpt Hb-
12.1, wbc-8.9, plt-398
rabiya i16022796 60 f
non hodgkins lymphoma - small 
lymphocytic lymphoma [SLL] & 
vitamin b12 deficiency
loss of appetite,fatigueability, 
dyspnea+, palpitation & weight 
loss+
pedal edema+, hepatomegaly+, 
spleenomegaly+ 3.3 1.5 12 macrocytic normochromic anaemia - anisopoikilocytosis+ not done in adequate
bone trabeculae enclosing hypercellular marrow spaces. 
Marrow spaces shows infiltration by sheets of small round cells 
with scanty cytoplasm & round hyperchromatic mcv-95, ldh- 117, vitamin B12- 113, folate- 10.4, viral serology negative
10 days later- hb-7.6, wbc-
1.6, plt-10
ramya i16023185 38 f dengue fever with hepatitis fever,mylagia,headache mild pallor+ 10 3 80 normocytic normochromic anemia - lymphocytosis ++ & activated lymphocytes + not done
not done
not done mcv-76,sgot-248, sgpt-127, mcv-76,dengu Igm postive, usg abdomen-normal
rpt hb-11,tc-5.5,plt-
245,sgpt-40,sgot-33
dharmaraj i16022964 76 m
megaloblastic anaemia-vitamin B12 
deficiency [mixed diet] loss of appetite, weight loss -10kg pallor+ 6.8 3.2 36
dimorphic anaemia - predominantly macrocytic normochromic. Anisopoikilocytosis 
+,elliptocytes+,tear drop cells+,basophilic stippling+,polychromasia+,schistocytes+ not done
hypercellular for age & show erythroid series show 
megaloblastic maturation with mild 
dyserythropoiesis[nuclear budding/briding,howell jolly 
bodies]ring neutrophils+,multinucleated megakaryocytes + 
- f/s/o megaloblastic anaemia
hypercellular marrow - erythroid series show -hyperplasia with 
megaloblastic maturation. Myeloid precursors- sequential 
maturation with occasional gaint forms, few megakaryocytes 
seen. mcv-108,rdw-37.2,mpv-8.3,ldh-2808,vitamin B12 -<30,folate -5.94, [not done] no follow up
pavithra i16026297 22 f
acute febrile illness, extra hepatic 
portal vein obstruction, 
hypersplenism fever,headache pallor,massive spleenomegaly+ 7.9 0.4 38 microcytic hypochromic anaemia with leukopenia. Anisopolikocytosis+ iron-31,tibc-284,ferritin-33
trilineage hematopoiesis with lymphocytosis
normocellular - trillineage hematopoiesis with focal mild 
increase in lymphocytes
mcv-73,tsh-1.90,ft4-1.01,folate-8.51,vitamin b12-286, ldh-166,usg colour doppler 
abdomen- chronic portal venous occlusion;gross spleenomegaly;portal 
hypertension. Usg abdomen- gross splenomegaly,narrow calibre portal vein with 
thin flow. Ugi scopy-grade a esophagitis, lax les,bile reflux gastritis
1 month later- hb-10.2,tc-
3.3,plt-64. 2 month later-
hb-12,tc-4.7,plt-69. 5 
month later - hb-12.1,tc-
4.6,plt -54
balamurgan i16026213 23 m  myelodysplastic syndrome leg swelling,fatigueability
pallor+,pedal edema+,facial 
puffiness+ 8.2 3.2 9
normocytic normochromic to microcytic hypochromic anaemia with thrmbocytopenia. 
Anisopoikilocytosis+,activated lymphocytes+ not done
hypercellular, erythropoesis-normoblastic to 
megaloblastic maturation[dyserythropoiesis], 
myelopoiesis-suppressed with sequential maturation,gaint 
bands & myelocytes are seen [dysgranulopoiesis + 
.megakaryopoiesism-decreased. Abnormal cells [blast-8%], 
increased N:C ratio,irregular nuclei & 1-2 prominent 
nucleoli,
normocellular marrow with megakaryocytic hypoplasia & 
dysplasia & aggregates of suspicious cells.
mcv-86,vitamin b12-1536,folate-7.86,ldh-203,uric acid-2.1,hiv-neg,usg abdomen- 
normal. Alp-192
sarasa i16026940 55 f
massive splenomegaly with 
hypersplenism, folate deficiency, 
portal hypertension, ? Non cirrhotic 
portal fibrosis, esophageal 
varices,hypothyrdism
abdominal distension,malena,blood 
vomitus,h/o weight loss+ 
&diarrhoea
pallor+,b/l pedal 
edema+,massive 
splenomegaly+ 5.6 1.3 49 microcytic hypochromic to normocytic hypochromic anemia - marked anisopoikilocytosis+ iron-22,tibc-452,ferritin-10
f/s/o-combimed nutritional deficiency anemia with 
predominatly iron deficiency component with reactive 
megakaryocytic hyperplasia
normocellular to mildly hypercellular - suboptimal biopsy 
showing erythroid hyperplasia
mcv-73,viral serology- negative, tsh-97,ft4-0.17.vitamin B12-596,folate-3.78,lft-
normal,usg colour doppler abdomen-f/s/o portal hypertension,ugi scopy-
esophageal varices grade 2-3,mild portal gastropathy. Usg abdomen- chronic liver 
parenchymal disease with portal hypertension,gross splenomegaly,minimal free 
fluiss in pelvis.
10 days later-hb-9.7,tc-
3.3,plt-65. 1 month later 
hb-10.9,tc-1.9,plt-57. 
ceruloplasmin-28.9. ANA 
prifile & liver profile - 
negative.
kalaiselvan i16032921 50 m
megaloblastic anaemia-vitamin B12 
deficiency [mixed diet]
yellowish discolouration of 
eyes,loss of appetite,abdominal 
discomfort,easy 
fatigueability,dyspnea, weight 
loss+ pallor+,icterus+ 5.5 3.8 82
macrocytic normochromic anaemia - severe anisopoikilocytosis+ & hypersegmental 
neutrophils+,elliptocytes+,tear drop cells+, iron-177,tibc-293,ferritin-291
megaloblastic anemia with ineffective hematopoiesis - 
bone marrow smear are hypercellular due to marked 
erythroid hyperplasia, erythropoiesis show megaloblastic 
maturation with dysplastic features.
hypercellular marrow - erythroid hyperplasia
mcv-100.3, rdw-40.5,mpv9.8,ana profile & ana if -neg, hiv-neg,duodenal biopsy- 
tropical sprue[lax lower esophageal sphincter,duodenogastric reflux normal],LDH-
8945,vitamin B12-56,folate-5.44,anti TPO-8.16,  reticuocyte count -uncorrected -
1.0, usg abdomen - subtle coarse echotexture of liver.
15 days later hb-11.0,tc-
5.7,plt-545
sivasamy i16032474 26 m
megaloblastic anaemia-vitamin B12 
& folate deficiency, hypothyrodism, 
addisons disease[veg] fever, loose stools, fatiguability
pallor+, hyperpigementation of 
palms and toungue. 3.5 2 98
anisopoikilocytosis, hypersemental neutrphils+,polychromasia+, nucleated rbc+,elliptocytes+,tear 
drop cells+,schitocytes+,gaint platelets+ - predominently macrocytic normochromic anemia iron-272,tibc-311,ferritin-128
f/s/o - megloblastic anemia [2008]
hypercellular marrow - f/c/w megaloblastic anemia
mcv116.8,rdw-25.3,mpv-11.6,vitamin B12-96,folate-3.91,tsh-12.90,ft4-1.35,lft- 
bilirubin[t]-2.9,[d]-0.9,[id]-2.0,duodenal biopsy-tropical sprue[lax lower 
esophageal sphincter,duodenogastric reflux, normal].
5 months later , hb-17.5,tc-
8.6,plt-143
damodharan i16038970 65 m
megaloblastic anaemia [veg] - 
vitamin b12 & folate deficiency fatigueability,giddiness+ pallor+ 6.9 3 79
macrocytic normochromic anaemia - anisopoikilocytosis+, hypersegmental 
neutrophils+,elliptocytes+.tear drop cells+,basophilic stppling+,macro ovalocytes+. not done
inadequate
hpercellular marrow 
mcv-98, rdw-32.3,mpv-9.2,vitamin B12-90,folate-1.79, tsh-3.010,LDH-1101,retic 
count- 0.1%,bilirubin[t]-1.6,[d]-0.5,[id]-1.1,hiv-neg,usg abdomen-liver shows 
subtle echotexture,duodenal biopsy- tropical sprue[lax lower esophageal 
sphincter,fundic gland polyp,scalloping fold] no follow up
shanthamani i16039449 50 f
megaloblastic anaemia-vitamin B12 
& folate deficiency [veg] fatiguability,loss of appetite pallor+,pedal edema+,jvp raised 3.1 3.4 52
dimorphic anaemia- anisopoikilocytosis+, hypersemental neutrophils+,elliptocytes+,tear drop 
cells+,basophilic stippling+,macroovalocytes+. iron-148,tibc-209,ferritin-207
megaloblastic erythroid hypeplasia + bare nuclei
hypercelluar marrow - megaloblastic erythroid hyperplasia
mcv-96,rdw-32.3,mpv-9.2,ldh-6628,corrected retic count-0.03, ana profile & ana 
if -neg, vit B12-77,folate-3.38,tsh-2.370,ft4-1.35,ldh-6628,lft - bilirubin[t]-1.8,[d]-
0.5,[id]-1.3, duodenal biopsy-non specific duodenitis[lax lower esophagel 
sphincter,fundic gland polyp,scalloping fold].
2 months later, hb-12.1,tc-
8.4,plt-238
bangaru i16039102 70 f light chain myeloma
hip joint pain,loss of appetite, 
weight loss
pallor+,pedal edema+,b/ 
axillary lymph node 
+,hepatomegaly+,splenomegaly
+ 4.6 2 10 macrocytic normocytic normochromic. Atypical cells/blast-13% - anisopikiocytosis +, immature wbc++ not done
presence of immature cells[blast] mixed with few mature 
plasma cells against the background of exaggerated 
rouleux formation suggg- possibility of plasma cell 
dyscrasia
cellularity cannot be assesed - f/s/o-plasma cell dyscrasia 
consistent with myeloma. >5% of the immature cells are CD138 
postive.scattered cells are also seen to be MPO postive
mcv-99.1,esr-120,corrected retic count-1.0,urine bence zones protein -
neg,protein[t]-5.8,alb-3.1,glo-2.7,vitamin B12-830,folate-5.08,LDH-357.uric acid-
6.9,protein electrophoresis-indictes a decrease in albumin with an elevated in 
gamma globulin,no abnormal bands.viral serology -neg,usg abdomen-
hepatomegaly,splenomegaly,dilated portalvein. flow cytometry for acute leukemia 
pannel & immunofixation study showed igG +ve, light chain kappa & lambda 
elevated. no follow up
jaya suriyan i17003345 17 m
megaloblatic anaemia-vitamin B12 
deficiency  [veg]
loss of 
appetite,fatigueability,malena,gidd
iness,vomitng pallor+ 7.3 2.1 82
macrocytic normochromic anemia- anisopoikilocytosis+,hypersemental 
neutrophils+,microcytes+,elliptocytes+,tear drop cells+,schistocytes+. iron-50,tibc-287,ferritin-320
hypercellular,marked erythroid hyperplasia which displays 
megaloblastic maturation, dyserythropoesis in the form of 
nuclear budding,nuclear bridging,multi nuclearity and 
howel jolly bodies is seen - megaloblastic anemia with 
ineffective hematopoiesis.
hypercellular marrow - megaloblastic erythropoiesis
mcv-110,rdw-34.7,mpv-8.7,esr-63,vitamin B12-117,folate-3.07,anti TPO-
13.51,tsh-0.839,ft4-1.09,ldh-3351,bilirubin[t]-2.1,[d]-0.6,[id]-1.5,hiv-neg,ana 
profile & ana if -neg,usg abdomen- mild splenomegaly,duodenal biopsy - tropical 
sprue[lax lower esophagel sphincer,scalloping fold],anti ttg-negative.
10 days later,hb-9.9,tc-
6.9,plt-498. 6 months 
later, hb-15.9,mcv-86,tc-
8.3,plt-202
sangeetha i17005328 21 f dengue fever fever,mylagia, headache+ pallor+ 9.5 2.7 10 normocytic hypochromic anaemia with bicytopenia - anisopoikilocytosis & activated lymphocytes + not done
not done
not done mcv-76,smear for mp-neg,dengue igM -postive,sgpt-38,sgot-91 no follow up
ganeshan i17004160 51 m
megaloblastic anaemia - vitamin 
b12 & folate deficiency [mixed diet]
dyspnea,yellowish discolourisation 
of skin+,fatiguability pallor+ 4.2 1.9 18
macrocytic & microcytic hypochromic anemia - anisopoikocytosis,hypersegmental neutrophils+ & 
activated lymphocytes+,macroovalocytes+,tear drop cells+,schistocytes+,elliptocytes+,howell jolly 
bodies,nucleated rbcs+,gaint platelets+. iron-280,tibc-314,ferritin-455 f/c/w- megaloblastic anemia
hypercellular marrow - normoblastic to megaloblastic erythroid 
hyperplasia
mcv-118,rdw-29.1,mpv-8.9,esr-90,corrected retic count-0.48,viamin B12-
87,folate-1.40,ldh-783,bilirubin[t]-2.2,[d]-0.7,[id]-1.5,viral serology -neg,Duodenal-
biopsy - peptic duodeniti,D-1-gastric hetrotopia,gastric biopsy- h.pylori ass with 
chronic gastritis[erythematous & antral gastritis normal].usg abd-mild coarse 
liver echotexture,mild prostatomegaly
10 days later hb-8.4,mcv-
100,tc-9.0,plt-524
nandhakumar i17000110 27 m
megaloblastic anemia[diagnosed 
based on bone marrow]  [mixed 
diet] fever,giddiness
pallor+,icterus+,hyperpigmenta
tion + over palms & 
soles,spleenomegaly 6.4 3.9 98
Microcytic hypochromic to macrocytic normochromic anaemia - anisopoikilocytosis+, hypersegmental 
neutrophils+ & lymphocytosis, macrovalocytes,tear drop cells,polychromasia,spherocytes,nucleated 
rbcs,gaint platelets+ not done
erythroid hyperplasia with megaloblastic maturation & 
significant dyspoiesis especially in the megakaryocyte
hypercellular marrow with megaloblastic erythroid hyperplasia
mcv-116,rdw-26.3,mpv-11.5,esr-106,vitamin b12-404,folate-6.89,cortisol-
11.61,viral serology-neg,dengue & scrub - neg.usg abdomen-fatty 
liver,splenomegaly+,duodenal biopsy-peptic duodenitis [scalloping folds] no follow up
sinduja i16040193 23 f aplastic anemia
bleeding per vagina, 
fatigueability,purpuritic spot over 
the hands & legs+ purpuritic spots+ lower limb 7.3 3.6 29 macrocytic normochromic anemia- anisopoikilocytosis+,hypersemental neutrophils+ not done
f/s/o - megloblastic anemia
hypocellular with patchy areas of cellularity showing erythroid 
preponderence. mcv-103,esr-50,vitamin B12-165,tsh-1.39,ana profile,anca & ana if -negative. no follow up
bathirammal i16040397 20 f aplastic anemia
bleeding per 
vagina,palpitation,fatigueability, 
bleeding gums,dyspnea+ pallor+ 2 3.7 7
normocytic normochromic,normocytic hypochromic to macrocytic normochromic - 
anisopoikilocytosis+ iron-32,tibc-312,ferritin-179
hypocellular bone marrow aspiration smears showing 
features of relative erythroid hyperplasia with 
haemophacytosis. hypocellular marrow with consistent with aplastic anemia.
mcv-95,corrected reticulocyte count-1.68,vitamin b12-415,folate-5.11,ldh-116,tsh-
4.230,ft4-1.20,lft-normal,ana profile & ana if-negative.usg abdomen-mild 
hepatomegaly
1 month later hb-7.5,tc-
7.6.plt-10
kaliammal i17003600 63 f
?hemophagocytic 
lymphohistocytosis,acute infract in 
MCA territory
fever,loss of appetite,loss of 
weight+ pallor+,splenomegaly+ 5.5 3.1 17 microcytic hypochromic anemia- anisopoikilocytosis+ iron-17,tibc-279,ferritin-631
imprint- cellular with mild preponderance of blast
hypercellular marrow with erythroid hyperplasia
mcv-65,esr-136,retic count-0.7,smear for mp-neg,ldh-505,uric acid-9.4,bilirubin[t]-
0.7,[id]-0.3,[d]-0.4,protein[t]-6.1,alb-2.6,glo-3.5,urea-124,creatinine-2.64,tsh-
0.42,protein electrophoresis-slight fall in albumin & slight rise in gamma globulins-
sugg of inflammatory/infection.triglycerides-424,viral serology-neg,lepto,scrub & 
dengue-neg,ana profilr & ana if-negative.usg abdomen-splenomegaly+.mri brain-
rt MCA territory infract. refer to jpmer
hema i17005886 35 f
dengue fever, sever iron deficiency 
anemia fever,headache,mylagia pallor+ 6.3 2.5 90 not done iron-13,tibc-418,ferritin-4
not done
not done mcv-56,tsh-2.310,mcv-65.3,esr-21,dengue igM -postive,usg abdomen-normal. no follow up
kalaiselvi
i17008174, 
i17007816 33 f hypersplenism
abdominal distension,loss of 
appetite pallor+,splenomegaly+ 10 1.9 47 microcytic hypochromic anemia with leukopna & thrmbocytopenia-anisopoikilocytosis + not done
corroborative with hypersplenism
hypercellular bone marrow with erythroid hyperplasia, there is 
no evidence of infiltrative or granulomas in the marrow studied.
mcv-63.4,esr-19,bilirubin[t]-0.6,[d]-0.3,[id]-0.3,sgpt-68,sgot-62,alp-226,protein[t]-
5.5,alb-2.9,glo-2.6.spleen biopsy-benign vascular lesion s/o-diffusesinusoidal 
hemangiomatosis, liver biopsy-normal.usg abdomen-subtle coarse 
echotexture,dilated portal & spleenic vein,massive splenomegaly
10 days later hb-7.6,tc-
7.1,plt-1231. 2 months 
later hb-9.2,tc-5.8,plt-488
arumugam i17007272 69 m
megaloblastic anaemia- vitamin b12 
& folate deficiency [mixed diet] easy fatigueability pallor+,icterus+ 3.4 0.8 16
severe dimorphic anemia[microcytic hypochrmic to macrocytic normochromic]- anisopoikilocytosis 
+,elliptocytes+,schistocytes,tear drop cells,micro spherocyte,target 
cells,macroovalocyte,polychromasia,gaint platelets. iron-188,tibc-200,ferritin-473
f/c/w megaloblastic anemia
hypercellular marrow with erythroid hyperplasia
mcv-97,rdw-39.7,mpv-8.0,esr-40,retic count-0.2,vitamin B12 -94,folate-1.56,ldh-
849,bilirubin[t]-1.7,[d]-0.6,[id]-1.1,protein[t]-5.6,alb-3.3,glo-2.3,usg abdomen-
normal [not done] no follow up
ramesh waran i17008706 50 m
megaloblastic anaemia-vitamin b12 
& folate deficiency [mixed diet] leg swelling,fatigueability
pallor+,pedal 
edema+,hepatomegaly+,spleno
megaly+ 6.8 0.5 68
normocytic normochromic to macrocytic normochromic anaemia-anisopoikilocytosis+, 
macroovalocytes,tear drop cells, polychromasia iron-34,tibc-224,ferritin-1232
f/c/w -megaloblastic anemia
hypercellular marrow with erythroid hyperplasia
mcv-98.3,rdw-19.6,mpv-8.8,esr-64,vitamin b12-89,folate-0.96,bilirubin[t]-1.4,[d]-
0.5,[id]-0.9,usg abdomen-hepatomegaly+,splenomegaly+ [not done] no follow up
nathya i17009192 25 f
megaloblastic anaemia-vitamin b12 
& folate deficiency [mixed diet]
fever,loose 
stools,fatigueability,vomiting pallor+,spleenomegaly+ 4.1 3.5 37
macrocytic normochromic picture- anisopoikilocytosis+, immature blast +, hypersegmental 
neutrophils+,howell jolly bodies,basophilic stippling,microspherocytes,polychromasia,nucleated rbcs. not done
megaloblastic erythroid hyperplasia- megaloblastic 
anaemia
hypercellular marrow - megaloblastic erythroid hyperplasia
mcv-115,rdw-35.4,mpv-8.6,ldh-2830,reticulocyte count-5.4,tsh-4.630ft4-
1.01,vitamin b12-<50,folate-0.76,usg abdomen-mild splenomegaly.duodenal 
biopsy-mild non specific duodenitis[grade A reflux esophagitis, normal].
10 dyas later hb-10.6,tc-
8.7,plt-403
arulalaan i17009623 48 m
megaloblastic anaemia-vitamin b12 
& folate deficiency + 
neuroendocrine neoplasm [veg] dyspnea,loose stools pallor+ 4.6 2.9 45
macrocytic normochromic anaemia - ansiopoikilocytosis,hypersegmental neutrophils+,basophilic 
stippling,howell jolly bodies,elliptocytes,tear drop cells,schistocytes iron-247,tibc-279,ferritin-451
erythroid hperplasia
hypercellular marrow - f/c/w megaloblastic anemia
mcv-124,rdw-17.1,mpv-9.7,esr-118,retic count-0.8,tsh-5.240,ft4-1.13,vitamin b12-
69,folate-1.60,ldh-2267,usg abdomen-splenomegaly, duodenal biopsy - 
neuroendocrine neoplasm[scalloped duodenal folds,umblicated lesion]
10 days later hb-8.2,tc-
10,plt-164.2 months later 
hb-14.5,tc-13.5,plt-275
MASTER CHART
NAME IP NO AGE SEX DIAGNOSIS SYMPTOMS EXAMINATION HB WBC PLT PERIPHERAL SMEAR ANAEMIA PROFILE BA BX OTHER TEST FOLLOW UP
musthafa i17008568 57 m ? Aplastic anaemia
fatigueability,dyspnea,loss of 
appetite pallor+ 7.1 1.2 7 normocytic normochromic anaemia not done
in adequate
hypoplastic marrow - ? Aplastic anemia
mcv-92,esr-129,urine benze zone proteins-neg,vitamin b12-556,folate-
8.51,bilirubin [t]-1.4,[d]-0.8,[id]-0.6,proteins[t]-6.9,alb-3.1,glo-3.8,ldh-199,uric 
acid-3.0,tsh-0.705,viral serology-neg,ana profile-neg,ana if-neg,usg abdomen-fatty 
liver. reffer to hematologist
padmavathi i17009829 42 f
dimorphic anaemia-severe iron 
deficiency anaemia & vitamin b12 
deficiency
fatigueability,palpitation,facial 
puffiness,pedal edema,dyspnea. pallor+,pedal edema+ 3.5 2.2 95 microcytic hypochromic anaemia- anisiopoikilocytosis+, normal iron-8,ferritin-2,tibc-493
erythroid hyperplasia ,megaloblastosis, and gaint myeloid 
precursors.scattered megakaryocytes.
hypercellular marrow - erythroid & megakaryocytes hyperplasia
mcv-62,rdw-22.2,mpv-8.6,esr-66,sob-neg,vitamin b12-138,folate-8.22,duodenal 
biopsy-normal[lax lower esophageal sphincter,normal],usg abdomen-mild 
spleenomegaly
2 months later rpt hb-
7.9,tc-3.5,plt126
parvathi i17010456 40 f
megaloblastic anaemia-vitamin b12 
deficiency, atropic gastritis 
[vegetarian] fatigueability,dyspnea, palpitation pallor+,icterus+,pedal edema 3.8 3.9 22
macrocytic anaemia with thrmbocytopenia- anisopoikilocytosis +, hypersegmented neutrophils+, 
occasional immature wbc+,polychromasia iron-31,tibc-365,ferritin-1018
f/s/o-megaloblastic anaemia
hypercellular marrow - megaloblastic erythroid hyperplasia & 
megakaryocytic hyperplasia consistent with the peripheral 
anaemia
mcv-101,rdw-36.4,mpv-8.7,esr-120,vitamin b12 -<50,folate->20,bilirubin[t]-
2.1,[d]-1.4,[id]-0.7,sgpt-39,sgot-162,alp-126,tsh-1.370,ft4-1.13,ldh-7433, d dimer-
5.6,ana profile- neg,rf-neg,ana if-postive [fine cytoplasmic speckles jo 1 
patern,nuclear pattern+],anti leptospira -neg.usg abdomen -
hepatomegaly,spleenomegaly+, duodeneal biopsy-foveolar metaplasia[atropic 
gastritis,scalloping duodenal folds].
10 days later hb-7.1,tc-
5.6,plt-230
ramayee i17007743 57 f
hypersplenism,non cirrhotic portal 
fibrosis,portal 
hypertension,oesophageal varices
bleeding gums,epistaxis, 
fatigueability pallor+,hepatospleenomegaly 4.4 2.7 98 microcytic hypochromic anaemia with eosinophilia -anisopoikilocytosis + not done
not done
hypercellular marrow -  with erythroid hyperplasia and 
megaloblastic changes
mcv-63,esr-45,bilirubin[t]-0.4,[id]-0.1,[d]-0.3,liver biopsy- liver biopsy-f/c/w-non 
cirrhotic portal hypertension
vasanth i17009680 39 m
iron deficiency anaemia, dengue 
fever
fever,headache,tiredness,cough 
with expectoration pallor+,hepatomegaly+ 4.7 2.7 60 microcytic hypochromic anaemia - anisopoikilocytosis+ iron-12,tibc-414,ferritin-10
f/c/w-iron deficiency anaemia. There is marked 
megakaryocyte hyperplasia corresponding to peripheral 
thrmbocytopenia normocellular marrow - in sufficient
mcv-54,esr-36,retic count-0.7,vitamin b12-427,folate-5.88,tsh-0.43,hiv,hbsag,hcv 
were negative,dengue ns 1 ag-postive,ana prfile-neg, usg abdomen-prominent 
hepatic veis & ivc,mild splenomegaly
10 days later rpt hb-9.1,tc-
5.2,plt-410
ammasai i17011294 85 m
megaloblastic anaemia- folate 
defiiency [veg]
dyspnea,slurring of 
speech,fatigueability normal 4.7 3.9 43
macrocytic normochromic anaemia - anisopoikilocytosis+,hypersemental 
neutrophils+,lymphocytosis+,carbot ring,basophilic stippling,elliptocyte,tear drop 
cells,macroovalocyte,nucleated rbc,gaint platelets iron-178,tibc-259,ferritin-277
f/c/w-megaloblastic anaemia with ineffective 
haematopoiesis
hypercellular marrow with erythroid hyperplasia
mcv-91,rdw-19.0,mpv-10.1,retic count-1.5,esr-95,vitamin b12->2000,folate-
<0.600,ldh-2018,bilirubin[t]-2.9,[d]-0.5,[id]-2.4,tsh-1.46,haptoglobin-15.5,dengu 
serology-neg,scrub - neg,hiv- neghbsag-neg,hcv-neg,usg abdomen-mild 
splenomegaly, [not done]
15 days later rpt hb-
12.1,tc-5.7,plt-189
gayathri i17012639 25 f
dengue fever,non cirrhotic portal 
fibrosis,hypersplenism fever,vomiting,mylagia,headache pallor+ 9.7 0.7 33 hypochromic anaemai - anisopoikilocytosis+ not done
not done hypercellular marrow - with micronormoblastic erythroid 
hyperplasia mcv-75,esr-43,dengue igm-postive
1 month later rpt hb-
11.1,tc-3.9,plt-47
muthuvelappan i17013571 65 m
megaloblastic anaemia- folate 
deficiency [mixed diet]
paraesthesia of b/l foot,loss 
appetite,fatiueability pallor+ 3.8 3.4 88
pancytopenia with macrocytosis of rbc - anisopoikilocytosis,activated lymphocytes+,ovalocytes,tear 
drop cells,schistocytes,gaint platelets not done
diluted 
hypercellula marrow  - erythroid hyperplasia
mcv-112,rdw-17.6,mpv-8.3,ldh-3827,esr-115,corrected retic count-0.3,usg 
abdomen-cholelithiasis,minimal rt pleural efffusion,vitamin b12->2000,folate-
4.18,ldh-3827,ugi scopy-bile reflux gastritis,mild scalloped duodenal 
folds,duodenal biopsy-trpical spure[scalloped duodenal folds].mri brain-multiple 
areas of periventricular white matter hyper intensities predominently in the peri 
callosal region & subcortical white matter in LT parietal lbe 
pavithra i17010398 18 f
dengue hemorrhagic fever,viral 
infection induced hemophagocytic 
lympho histiocytosis [secondary 
HLH syndrome],coexsisting cmv & 
ebv infection. fever,vomiting, mylagia pallor+ 8.7 1.8 60 microcytic hypochromic anaemia - anisopoikilocytosis+, activated lymphocytes+ iron-26,tibc-327,ferritin->2000
erythroid hyperplasia & haemohagocytosis
normocellular marrow - erythroid hyperplasia
mcv-56,esr-8,corrected retic count-4.02,bilirubin[t]-1.9,[d]-1.5,[id]-0.4,sgpt-
460,sgot-1055,alp-269,protein[t]-4.5,alb-2.4,glo-2.1,ldh-3517,triglyceride-966,tsh-
4.580,ft4-1.38,haptoglobin-46.4,dengue igm postive,viral serology - negative,liver 
profile igG-negative,ana profile-neg,ana if- dense fine speckles,cmv igm - postive, 
ebv igg postive,usg abdomen-altered echotexture of liver,mild ascities,b/l mild 
pleural effussion.
8 days later rpt hb-10.2,tc-
8.9,plt-186.2 months later 
-rpt hb-11.7,tc-5.8,plt-
298.rpt sgpt-46,sgot-
35,triglyceride-125,ferritin-
361
radhakrishnan i17016170 56 m myelodysplastic syndrome
blisters over 
extrimities,fever,cough with 
expectoraton pallor+,pedal edema,blisters+ 8 3.9 20
f/o-intracascular haemolysis - predominantly microcytic hypochromic picture,hypersegmental 
neutrophils+,immature wbc+,anisopoikilocytosis+ not done
f/s/o-megaloblastosis & dyspoiesis 
hypercellular marrow - possibility of myelodysplastic 
syndrome[RAEB-refractory anaemia with excess blast]
mcv-73,esr-25,corrected rectic count-0.5,urine test postive for 
haemoglobinuria/myoglobinuria,HAMSA TEST -NEGATIVE, SUCROSE LYSIS TEST - 
negative,ldh-466,uric acid-2.9,c3-56,c4-12,haptoglobin-138,ferritin-
1152,cryoglobulin-14.3vitamin b12->2000,folate-14.99,viral serology-neg,ana 
profile -neg,ana if-neg,anca-neg.usg abdomen-moderate ascities,b/l small pleural 
effusion.direct coombs test-wealky postive,flow cytometry for CD55 & CD 59 was 
negative.skin biopsy-leukocytoclastic vasculitis.
palanisamy i17016803 69 m
lymphoma - non hodgkins 
lymphoma loss of appetite,fever
pallor+,hepatomegaly,splenom
egaly 7.7 1.5 81 pacytopenia with activated lymphocytes+ - normocytic normochromic to macrocytic normochromic iron-19,tibc-178,ferritin-670
f/s/o-lymphoplasmacytic infiltrate in the marrow suggest 
the following possibilities - lymphoplasmacytic lymphoma 
& small b cell lymphoma with plasmacytic differentiation
hypocellular marrow - lymphoplasmacytic infiltrate in the bone 
marrow - lymphoplasmacytic lymphoma & small b cell 
lymphoma with plasmacytic differentiation
mcv-97,esr-96,ldh-209,viral serology-neg,usg abdomen-
hepatosplenomegaly,dilated portal vein,gall bladder sludge,prostatomegaly. Creat-
1.21,bilirubin [t]-0.7,[d]-0.4,[id]-0.3,protein [t]-7.1,alb-2.8,glo-4.3. reffer to higher centre
sadhasivam i17017488 43 m
megaloblastic anaemia-vitamin b12 
deficiency [veg]
fever,loose stools, vomiting, 
fatigueability,breathing difficulty pallor+,icterus+ 4 2 33
microcytic hypochromic to macrocytic normochromic - anisopoikilocytosis +, hypersegmental 
neutrophils+ & lymphoctosis +,elliptocytes,tear drop cells,macroovalocytes,spherocytes,basophillic 
stippling,nucleated rbc not done
hypercellular marrow & shows megaloblast in plenty - 
megaloblastic anaemia with ineffective haemotopoiesis
hypercellular marrow with megaloblastic maturation
mcv-119,rdw-42.0,mpv-9.2,esr-2,corrected retic count-0.5,bilirubin [t]-3.6,[d]-
0.4,[id]-3.2,protein[t]-7.0,alb-3.9,glo-3.1,haptoglobin-<10,ldh-4699,tsh-
2.170,creat-1.38,uric acid-9.8,vitamin b12 - 80,folate-6.63, ana profile-neg,ana I - 
neg, viral serology,usg abdomen-cholelithiasis [not done]
2 months later-hb-11.8,tc-
5.4,plt-224
balamani i17020269 61 f
megaloblastic anaemia-vitamin b12 
deficiency [veg]
fatigueability+,loss of 
appetite,weight loss+ pallor+ 4.5 2.1 98
macrocytic normochromic & microcytic hypochromic anaemia - 
anisopoikilocytosis+,elliptocyte,schistocyte,tear drop cells,gaint platelet. iron-101,tibc-222,ferritin-112
hypercellular with erythroid hyperplasia - megaloblastic 
anaemia with ineffective haematopoiesis
f/s/w-megaloblastic anaemia - hypercellular marrow
mcv-92,rdw-36.3,mpv-8.3,esr-80,retic count-0.8,bilirubin [t]-1.3,[d]-0.4,[id]-
0.9,protein[t]-6.7,alb-4.0,glo-2.7,ldh-5126,tsh-4.80,usg abdomen- normal [not 
done] no follow up
rukumani i17023135 65 f aplastic anaemia headache,fever,vomiting
pallor+,b/l lower limb 
petechiael spots+ 4.7 2.2 3 pancytopenia- anisopoikilocytosis+, activaed lymphocytes+ iron-249,tibc-271,ferritin-463
haemodiluted- few atypical cells +
hypoplastic bone marrow with patchy erythroid & lymphoid 
island.
mcv-109,esr-100,vitamin b12-200,folate-12.85,ldh-166,bilirubin [t]-0.7,[d]-0.3,[id]-
0.4,protein [t]-6.9,alb-3.9,glo-3.0,haptoglobin-107,uric acid-5.4,cea-1.3,ca-125-
10.63,ca 19-9-11.9,afp-2.0,ana profile-neg,ebv igG-postive,cmv-neg,ana if -
neg,dengue ns1 -neg,usg abdomen-normal,parvo virus b19-neg.
7 days later hb-7.7,tc-
6.5,plt-3
kaliappan i17027238 87 m
megaloblastic anaemia-vitamin b12 
[mixed diet]
fever,mylagia,loose 
stools,abdominal pain,altered 
sensorium disoriented 9.1 0.9 54
macrocytic normochromic anaemia - anisopoikilocytosis+, activated lymphocytes+,elliptocyte,target 
cells, not done
megaloblastic anaemia bone marrow aspirate
normocellular marrow - trilineage haematopoiesis with 
megaloblastic erythropoiesis
mcv-107,rdw-18.6,mpv-8.7,esr-55,smear for mp-neg,bilirubin [t]-0.5,[d]-0.2,[id]-
0.3,protein [t]-5.5,alb-3.2,glo-2.3,uric acid-2.5,vitamin b 12-<50,folate-7.62,tsh-
0.635,protein electrophoreisis-normal pattern,hiv-neg,ana if- neg,dengue ns1 -
neg,usg abdomen-normal study [not done] ????????????
annakodi i17027161 35 f
megaloblastic anaemia-vitamin b 12 
& folate deficiency [mixed diet]
fatiguability,loss of appetite,loss of 
weight pallor+ 4.8 3.7 55 pancytopenia with macrocytes of  rbc - anisopoikilocytosis+, tear drop cells,ovalocytes iron-62,tibc-219,ferritin-67
megaloblastic anaemia with ineffective haematopoiesis
hypercellular marrow - with predominant megaloblastic 
erythroid hyperplasia
mcv-110,rdw-30.0,mpv-9.1,esr-1,corrected retic count -0.2,vitamin b12 -
<50,folate-1.43,tsh-1.94,ldh-4631,bilirubin [t]-1.0,[d]-0.2,[id]-0.8,protein [t]-
6.6,alb-3.6,glo-3.0,viral serology-neg,dengue ns1-neg,ana profile-neg,usg 
abdomen-normal, [not done] ???????
jayasudha i17027129 31
systemic lupus erythematosus with 
lupus nephritis facial puffiness & leg swelling
pallor+,pedal 
edema+,periorbital edema 3.4 2.9 64 normocytic normochromic to microcytic hypochromic anaemia - anisopoikilocytosis+ iron-30,tibc-110,ferritn-1702
haemodiluted
hypercellular marrow space, there is erythroid hyperplasia -
trilineage hematopoiesis
mcv-79,ana profile- sm postive,nucleosomes posive, histones postive, ana if 
postive- nucleus fine speckled+++,dense fine speckled cytoplasm+++. Renal 
biobsy-lupus nephritis class iv [a]-isn/rps classification 2004,c3-<30,c4-<4, 
vitamin b12->2000,folate-3.75`
palanimmal i17030045 62 f
non hodgkin lymphoma - follicular 
lymphoma
fever,leg swelling,loss of 
appetite,dyspnea
pallor,pedal edema+,oral 
thrush+ 5.7 3.7 99 normocytic normochromic anaemia - anisopoikilocytosis+ iron-30,tibc-139,ferritin-660
trilneage hematopoiesis with erythroid preponderance 
showing micronormoblast [?iron deficiency]
hypercellular marrow space - erythroid hyperplasia
mcv-77,esr-88,uric acid-17.3,ldh-631,vitamin b12->2000,folate-24.9,tsh-
0.647,cervical lymph node biopsy-atypical lymphoid cells strongly express CD20 
[b cell marker] & bcl imunostain, the surrounding reactive lymphocytes shows 
CD3 postivityn[t cell marker], ki67 [proliferative marker] is high >60%
tharrun kumar i17029284 19 m systemic lupus erythematosus
fever+,sore throat+,loss of weight, 
loss of appetite
oral ulcers+,b/l cervical lymph 
node+ 9.9 3.3 45 mild normocytic normochromic anaemia - lymphocytosis+, activated lymphocyes+ not done
normal erythroid & myeloid precursors cells.scattered 
macrophages with haemophagocytosis are observed normocellular marrow - megakaryocyte hyperplasia,there are no 
abnormal cells or granulomas in the sections studied mcv-78,esr-90,ana profile-sm ++,nucleosome ++,histones++.
nagarathinam i16022322 65 f plasma cell dyscrasias - mgus fever+,dyspnea,fatigueability pallor+ 3.9 2.9 6 anisopoikilocytosis+, lymphocytosis+ iron-122,ferritin-319,tibc-221
erythroid hyperplasia & plasmacytosis - plasma cell 
dyscrasia
inadequate - mild plasmacytosis
mcv-96,esr-140,urine for bence jones proteins -neg,tsh-6.63,vitamin b12-
568,folate->20,protein electrophoresis - mild elevation in gamma globulin-no 
abnormal band is seen.ana if-negativee,usg abdomen-fatty liver,beta 2 
microglobin-2740[high],immunoglobulin total igg-16.90,serum light chain - kappa 
59.20[high], lambda-39.60 [high]
najmudeen i17027965 45 m
megaloblastic anemia - vitamin 
b12,folate deficiency [mixed diet] fever,loose stools pallor+ 5.8 2.4 90
macrocytic normochromic anemia - lymphocytosis +, hypersegmental neutrophils+,basophillic 
stippling,howell jolly bodies,nucleated rbc, iron-142,tibc-193,ferritin-506
f/c/w -megaloblastic anemia
hypercellular marrow space- f/c/w- megaloblastic anemia
mcv-128,rdw-21.0,mpv-9.4,vitamin b12-<50,folate-1.25,deep duodenal biopsy-
c/w-tropical spure[duodenal villous atrophy]
baskar i17033639 48 m
megaloblastic anemia - vitamin b12 
& folate deficiency[mixed diet] fatigueability
pallor+,hyperpigmentation + 
over palm, splenomegaly+ 4.4 2.3 64 pancytopenia with macrocytosis - anisopoikilocytosis+,macroovalocytes,tear drop cells,schistocyte, iron-263,tibc-272,ferritin-1808
f/c/w-megaloblastic anemia
hypercellular marrow space- megaloblastic erythroid 
hyperplasia
mcv-133,rdw-19.1,mpv-10.8,ldh-1034,vitamin b12-162,folate-<0.600, usg 
abdomen - mild splenomegaly, duodenal biopsy - tropical sprue[normal mucoasal 
study]
subramani i17032954 47 m
chronic liverdisease with portal 
hypertension, megaloblastic anemia 
- vitamin b12 deficiency[mixed diet] fatigueability,dyspnea,weight loss+ pallor+,splenomegaly+ 4.8 1.6 25
pancytopenia with macrocytosis and atypical cells 3% - anisopoikilocytosis+,hypersegmental 
neutrophils+, immature wbc+ iron-63,tibc-329,ferritin-496
megaloblastic erythropoiesis
hypercellular marrow
mcv-101,rdw-16.2,mpv-9.3,vitamin b12-<50,folate-1.4,bilirubin [t]-1.8,d-0.6,id-
1.2,usg abdomen-liver parenchymal disease with portal hypertension,moderate 
splenomegaly.deep duodenal biopsy -tropical spure[pedunculated polyp- 
stomach]
